![]() |
![]() |
![]() |
![]() |
151-P | TARGETED SINGLE CELL SEQUENCING TO IDENTIFY MUTATIONAL HIERARCHY IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | Jolien De Bie | ![]() |
![]() |
|||
152-P | BCL-2 INHIBITION AS NEW THERAPEUTIC OPPORTUNITY FOR RPL10 R98S MUTANT PEDIATRIC T-ALL | Kim Kampen | ![]() |
![]() |
|||
153-P | TRANSLATOME ANALYSIS OF THE T-ALL ASSOCIATED RIBOSOMAL PROTEIN L10 R98S MUTATION REVEALS ALTERED SERINE METABOLISM | Laura Fancello | ![]() |
![]() |
|||
155-P | TP53 MUTATIONS DISRUPTING DNA BINDING LEAD TO CHEMOTHERAPY RESISTANCE IN ACUTE LYMPHOBLASTIC LEUKEMIA | Malwine Pogodzinski | ![]() |
![]() |
|||
156-P | GENETIC ACTIVATION AND THERAPEUTIC TARGETING OF PIM1 IN T-CELL ACUTE LYMPHOBLASTIC LYMPHOMA | Renate De Smedt | ![]() |
![]() |
|||
157-P | IL-7 FLEXIBLY REGULATES AUTOPHAGY-DEPENDENT VIABILITY OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA CELLS | Daniel Ribeiro | ![]() |
![]() |
|||
158-P | PRECLINICAL ACTIVITY OF ENTOSPLETINIB IN CHILDHOOD B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | Sarah Tasian | ![]() |
![]() |
|||
159-P | PHARMACOLOGICAL ACTIVITY OF CB-103 – AN ORAL PAN-NOTCH INHIBITOR WITH A NOVEL MODE OF ACTION | Raj Lehal | ![]() |
![]() |
|||
160-P | IKZF1?4-7 CAN BE EASILY SCREENED BY PCR BUT DOES NOT PREDICT OUTCOME IN ADULTS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA; DATA FROM 490 PATIENTS ENROLLED ON THE UKALL14 TRIAL. | Rachel Mitchell | ![]() |
![]() |
|||
161-P | PROGNOSTIC SIGNIFICANCE OF MINIMAL RESIDUAL DISEASE DETECTED BY MLL FUSION GENE TRANSCRIPTS IN INFANT ACUTE LYMPHOBLASTIC LEUKEMIA. UPDATED RESULTS OF 76 PATIENTS ENROLLED INTO MLL-BABY STUDY | Grigory Tsaur | ![]() |
![]() |
|||
162-P | PRO-T CELL ALL/LBL: AN ULTRA-HIGH RISK CD2-NEGATIVE DISEASE SUBTYPE IN ADULTS DEFINED BY FLOW CYTOMETRY | Beata Ostrowska | ![]() |
![]() |
|||
163-P | CLINICAL SIGNIFICANCE OF END OF INDUCTION MINIMAL RESIDUAL DISEASE IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMPLETE REMISSION AFTER A SINGLE CHEMOTHERAPY COURSE | Renato Bassan | ![]() |
![]() |
|||
164-P | RESULTS FROM UKALL60+, A UK/HOVON COLLABORATIVE PHASE 2 STUDY IN ELDERLY PATIENTS WITH UNTREATED ACUTE LYMPHOBLASTIC LEUKAEMIA | Nick Morley | ![]() |
![]() |
|||
165-P | CLINICAL OUTCOMES OF ELDERLY ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA – A SINGLE INSTITUTION EXPERIENCE | Kevin Miller | ![]() |
![]() |
|||
166-P | MANAGEMENT AND OUTCOME OF ADULT PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS TREATED AT THE "SAPIENZA" UNIVERSITY BETWEEN 1996 AND 2016 | Sabina Chiaretti | ![]() |
![]() |
|||
167-P | THE TETRASPANIN CD9 IS A PROGNOSTIC MARKER FOR PREDICTING SURVIVAL OUTCOMES OF PEDIATRIC B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA | Kam Tong Leung | ![]() |
![]() |
|||
168-P | PEDIATRIC MLL ACUTE LEUKEMIA PATIENTS SHOW DIFFERENTIAL HDAC EXPRESSION | Nerea Vega-Garcia | ![]() |
![]() |
|||
169-P | MINIMAL DISSEMINATED DISEASE DETECTION BY FLOWCYTOMETRIC IMMUNOPHENOTYPING IN T-CELL ACUTE LYMPHOBLASTIC LYMPHOMA | Ganesh Kumar Viswanathan | ![]() |
![]() |
|||
170-P | INOTUZUMAB OZOGAMICIN IN COMBINATION WITH LOW-INTENSITY CHEMOTHERAPY (MINI-HYPER-CVD) AS FRONTLINE THERAPY FOR OLDER PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA: UPDATED RESULTS FROM A PHASE I/II TRIAL | Nicholas Short | ![]() |
![]() |
|||
171-P | RECURRENT MYB REARRANGEMENT IN BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM | Kyogo Suzuki | ![]() |
![]() |
|||
172-P | BRANCHED CHAIN AMINO ACID METABOLISM REGULATES ALPHA-KETOGLUTARATE HOMEOSTASIS RESEMBLING MUTANT-IDH DRIVEN DNA HYPERMETHYLATION IN AML | Simon Raffel | ![]() |
![]() |
|||
173-P | NUCLEAR RE-LOCALIZATION OF NPM1C+ INDUCES DIFFERENTIATION AND CELL GROWTH ARREST | Lorenzo Brunetti | ![]() |
![]() |
|||
174-P | THE LONG NON-CODING RNA HOXB-AS3 REGULATES RIBOSOMAL BIOGENESIS IN NPM1-MUTATED ACUTE MYELOID LEUKEMIA | Dimitrios Papaioannou | ![]() |
![]() |
|||
175-P | A DUAL BH3-MIMETIC APPROACH TARGETING BOTH BCL-2 AND MCL1 IS HIGHLY EFFICACIOUS AND WELL-TOLERATED IN ACUTE MYELOID LEUKEMIA | Donia Moujalled | ![]() |
![]() |
|||
176-P | THE PMLC62A/C65A KNOCK-IN MOUSE MODEL PROVIDES EVIDENCE FOR THE ROLE OF NUCLEAR BODY DISRUPTION IN THE PATHOGENESIS OF ACUTE PROMYELOCYTIC LEUKEMIA | Edwige Voisset | ![]() |
![]() |
|||
179-P | ACUTE MYELOID LEUKEMIA EVOLUTION CAN BE RECONSTRUCTED BY ANALYSIS OF NON-LEUKEMIC CELLULAR SUBCOMPARTMENTS AND MULTI-LINEAGE ENGRAFTED MICE | Borhan Saeed | ![]() |
![]() |
|||
180-P | THE ESSENTIAL ROLE OF THE ENHANCERS OF POLYCOMB EPC1 AND EPC2 IN MLL-AF9 ACUTE MYELOID LEUKAEMIA IS A ´COMPLEX´ STORY | Niamh Mannion | ![]() |
![]() |
|||
181-P | STROMA-DERIVED FACTORS STIMULATE JAK/STAT SIGNALING IN AML CELLS RESULTING IN RESISTANCE TO BCL2 INHIBITOR VENETOCLAX | Riikka Karjalainen | ![]() |
![]() |
|||
183-P | H3K27ME3 LEVEL ON THE HIST1 CLUSTER: A POWERFUL EPIGENETIC BIOMARKER THAT STRATIFIES TWO GROUPS OF NPM1-MUTATED AML DIFFERING IN THEIR OUTCOME AND EXPRESSION PROFILE | Sylvain Garciaz | ![]() |
![]() |
|||
187-P | UNRAVELING EPIGENOMIC REGULATION IN THE EVOLUTION OF RELAPSING PEDIATRIC AML | Caroline Wiggers | ![]() |
![]() |
|||
188-P | MECHANISTICALLY INFORMED COMBINATIONS OF SY-1425, A POTENT AND SELECTIVE RAR? AGONIST, WITH HYPOMETHYLATING OR ANTI-CD38 TARGETED AGENTS IN AML AND MDS | Michael Mckeown | ![]() |
![]() |
|||
189-P | FLT3 INHIBITION OVERCOMES RESISTANCE TO THE BCL-2 SELECTIVE ANTAGONIST, VENETOCLAX, IN FLT3-ITD MUTANT AML MODELS | Deepak Sampath | ![]() |
![]() |
|||
190-P | SPECIFIC TARGETING OF ACUTE MYELOID LEUKEMIA STEM CELLS BY INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 7 | Linda Smit | ![]() |
![]() |
|||
192-P | PROGNOSTIC IMPACT OF SOMATIC MUTATION CLEARANCE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA | Koichi Takahashi | ![]() |
![]() |
|||
193-P | DO EDUCATION AND INCOME AFFECT TREATMENT AND OUTCOME IN ACUTE MYELOID LEUKEMIA IN A TAX-SUPPORTED HEALTH CARE SYSTEM? A DANISH NATIONAL POPULATION-BASED COHORT STUDY | Lene SG Østgård | ![]() |
![]() |
|||
194-P | IDENTIFICATION OF PATTERNS IN CO-OCCURRING MUTATIONS IN AML PATIENTS WITH GERMLINE AND SOMATIC RUNX1 MUTATIONS | Uma Borate | ![]() |
![]() |
|||
196-P | MULTIPLE LEUKEMIC STEM CELL MARKER EXPRESSION IS ASSOCIATED WITH POOR PROGNOSIS IN DE NOVO ACUTE MYELOID LEUKEMIA | Tomohiro Yabushita | ![]() |
![]() |
|||
197-P | NEXT GENERATION SEQUENCING TARGETED PANEL FOR MINIMAL RESIDUAL DISEASEMONITORING IN ACUTE MYELOID LEUKEMIA | Valerie Mcclain | ![]() |
![]() |
|||
198-P | IS IT POSSIBLE TO RELIABLY DETECT CLINICALLY-RELEVANT BIALLELIC CEBPA GENE MUTATIONS USING NGS PANELS? | Marta Fernandez-Mercado | ![]() |
![]() |
|||
200-P | NUMBER OF TP53 ABNORMALITIES AND THEIR CLINICAL RELEVANCE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES | Guillermo Montalban-Bravo | ![]() |
![]() |
|||
201-P | VADASTUXIMAB TALIRINE PLUS HYPOMETHYLATING AGENTS (HMA): A WELL-TOLERATED REGIMEN WITH HIGH REMISSION RATE IN FRONTLINE OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) | Farhad Ravandi | ![]() |
![]() |
|||
202-P | ACUTE MYELOID LEUKEMIA WITH INTERMEDIATE-RISK CYTOGENETICS AND A FAVORABLE GENOTYPE: PROGNOSTIC FACTORS AND RESULTS IN PATIENTS TREATED ACCORDING THE SPANISH CETLAM PROTOCOLS. | J. Sierra | ![]() |
![]() |
|||
204-P | A PHASE 2 STUDY OF GLASDEGIB (PF-04449913) IN COMBINATION WITH CYTARABINE AND DAUNORUBICIN IN UNTREATED PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) OR HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS) | Jorge Cortes | ![]() |
![]() |
|||
205-P | CM942 IS A NEW SMALL MOLECULE THAT TARGETS SET-PP2A INTERACTION AND INHIBITS GROWTH OF ACUTE MYELOID LEUKEMIA CELLS | Patricia García-Ramírez | ![]() |
![]() |
|||
206-P | CLONAL HETEROGENEITY IN LEUKEMIC STEM CELLS FROM PATIENTS WITH ACUTE MYELOID LEUKEMIA | Linda Manta | ![]() |
![]() |
|||
207-P | TREATMENT OF PRACINOSTAT AND AZACITIDINE IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML): CORRELATION BETWEEN MUTATION CLEARANCE AND CLINICAL RESPONSE | Koichi Takahashi | ![]() |
![]() |
|||
209-P | A RANDOMIZED PHASE II STUDY OF IDARUBICIN AND CYTARABINE WITH EITHER CLOFARABINE (CIA) OR FLUDARABINE (FIA) IN ADULTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA | Nicholas Short | ![]() |
![]() |
|||
210-P | OVERALL SURVIVAL AND TRANSPLANTATION IN PATIENTS WITH FLT3 MUTATIONS: SUBGROUP ANALYSIS OF A PHASE 3 STUDY OF CPX-351 VERSUS 7+3 IN OLDER ADULTS WITH NEWLY DIAGNOSED, HIGH-RISK ACUTE MYELOID LEUKEMIA | Bruno Medeiros | ![]() |
![]() |
|||
211-P | NIVOLUMAB MAINTENANCE THERAPY FOR PATIENTS WITH HIGH-RISK ACUTE MYELOID LEUKEMIA (AML) IN REMISSION | Tapan Kadia | ![]() |
![]() |
|||
212-P | HIGHER EXPRESSION OF LONG NON-CODING RNA KIAA0125 IS ASSOCIATED WITH CHARACTERISTIC CLINICAL AND BIOLOGICAL FEATURES AND IS AN INDEPENDENT POOR PROGNOSTIC FACTOR IN ACUTE MYELOID LEUKEMIA | Sheng-Yu Hung | ![]() |
![]() |
|||
213-P | LEUKEMIC STEM CELLS CAN BE DETECTED IN A CONSIDERABLE PERCENTAGE OF PATIENTS WITH ACUTE MYELOID LEUKEMIA AT DIAGNOSIS AND IS A SIGNIFICANT PROGNOSTIC FACTOR | Olga Pérez-López | ![]() |
![]() |
|||
214-P | POST-REMISSIONAL AND PRE-TRANSPLANT ROLE OF MINIMAL RESIDUAL DISEASE DETECTED BY WT1 IN ACUTE MYELOID LEUKEMIA: A RETROSPECTIVE COHORT STUDY | Chiara Frairia | ![]() |
![]() |
|||
217-P | OUTCOME OF PATIENTS WITH INTRAVASCULAR B-CELL LYMPHOMA, A RETROSPECTIVE STUDY CONDUCTED ON BEHALF OF THE LYMPHOMA STUDY ASSOCIATION (LYSA) GROUP | Antoine Bonnet | ![]() |
![]() |
|||
218-P | OUTCOME OF ELDERLY DLBCL PATIENTS (= 80 YEARS) TREATED WITH ANTHRACYCLINE BASED CHEMOTHERAPY; R-CHOP DOSE REDUCTION IS NOT NECESSARY FOR EVERYBODY | Marek Trnený | ![]() |
![]() |
|||
219-P | IMPROVED SURVIVAL IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL) UP TO AGE 70 ONLY: A POPULATION-BASED STUDY ON INCIDENCE, PRIMARY TREATMENT AND SURVIVAL IN THE NETHERLANDS, 1989-2015 | Avinash Dinmohamed | ![]() |
![]() |
|||
220-P | CLINICAL CHARACTERISTICS AND LONG-TERM RESULTS OF TREATMENT OF DIFFUSE LARGE HEPATITIS C - ASSOCIATED NON-HODGKIN LYMPHOMA (DLBCL + C). | Sergey Lepkov | ![]() |
![]() |
|||
223-P | RELAPSE CHARACTERISTICS AND THE ROLE OF SURVEILLANCE COMPUTED TOMOGRAPHY IN AGGRESSIVE NON-HODGKIN LYMPHOMA | Ka-Won Kang | ![]() |
![]() |
|||
224-P | A MULTI-CENTER STUDY OF GLIDE CHEMOTHERAPY CONSOLIDATED WITH AUTOLOGOUS STEM CELL TRANSPLANTATION FOR NEWLY DIAGNOSED STAGE IV AND RELAPSED EXTRANODAL NATURAL KILLER/T-CELL LYMPHOMA PATIENTS | Jie Ji | ![]() |
![]() |
|||
225-P | LONG TERM FOLLOW-UP OF PATIENTS WITH PERIPHERAL T-CELL LYMPHOMAS TREATED WITH IFOSFAMIDE, ETOPOSIDE, EPIRUBICIN / INTERMEDIATE METHOTREXATE AND AUTOLOGOUS STEM CELL TRANSPLANTATION | Michal Sieniawski | ![]() |
![]() |
|||
226-P | IDENTIFICATION OF A NOVEL GERMLINE MECOM / EVI1 VARIANT THAT RUNS IN A PEDIGREE WITH RADIOULNAR SYNOSTOSIS AND AMEGAKARYOCYTIC THROMBOCYTOPENIA AND PREDISPOSES TO ADULT ONSET MYELOID MALIGNANCY | Tim Ripperger | ![]() |
![]() |
|||
227-P | LOSS OF THE HOMOLOGOUS RECOMBINATION GENE RAD51 LEADS TO FANCONI ANEMIA-LIKE SYMPTOMS IN ZEBRAFISH | Jan Botthof | ![]() |
![]() |
|||
228-P | A NOVEL TELOMERASE RNA COMPONENT (TERC) VARIANT IN A FAMILY WITH MACROCYTOSIS AND MILD VARIABLE CYTOPENIAS | Claire Burney | ![]() |
![]() |
|||
229-P | GENERATION OF X-LINKED DYSKERATOSIS CONGENITA-LIKE HUMAN HEMATOPOIETIC STEM CELLS | Guillermo Guenechea | ![]() |
![]() |
|||
230-P | STUDY OF EXTRACELLULAR VESICLES ROLES IN THE PATHOPHYSIOLOGY OF THROMBOSIS IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS DURING ECULIZUMAB TREATMENT: A PILOT PROSPECTIVE LONGITUDINAL CLINICAL STUDY | Adeline Wannez | ![]() |
![]() |
|||
231-P | TELOMERE LENGTH SCREENING TRIGGERED BY CLINICAL SUSPICION FOR CLASSICAL AND/OR CRYPTIC DYSKERATOSIS CONGENITA –PROSPECTIVE RESULTS FROM THE AACHEN TELOMEROPATHY REGISTRY | Fabian Beier | ![]() |
![]() |
|||
233-P | CLINICAL AND GENETIC DIVERSITY IN DIAMOND-BLACKFAN ANAEMIA: AN UPDATE FROM THE UNITED KINGDOM | Deena Iskander | ![]() |
![]() |
|||
234-P | BONE MARROW FAILURE SECONDARY TO NOVEL/KNOWN PRIMARY IMMUNODEFICIENCY-RELATED MUTATIONS. A SINGLE CENTER ANALYSIS | Maurizio Miano | ![]() |
![]() |
|||
236-P | GERMLINE RARE VARIANT ASSOCIATION ANALYSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA | Jennifer Brown | ![]() |
![]() |
|||
237-P | DIFFERENTIAL ENHANCER TRANSCRIPTION ASSOCIATED WITH RISK ALLELE GENOTYPE IN CLL | Jennifer Brown | ![]() |
![]() |
|||
238-P | BIALLELIC TP53 GENE MUTATIONS DUE TO COPY-NEUTRAL LOSS OF HETEROZYGOSITY AND MONOALLELIC MUTATIONS IN ABSENCE OF 17P DELETION OCCUR IN CLL WITH COMPARABLE FREQUENCY | Karla Plevova | ![]() |
![]() |
|||
239-P | INTERGRATED OLIGO/SNP ARRAY- AND NEXT GENERATION SEQUENCING BASED ANALYSIS IS REQUIRED TO DETERMINE TP53/17P STATUS IN CLL PATIENTS | Marian Stevens-Kroef | ![]() |
![]() |
|||
240-P | CYTOGENETIC CLONAL EVOLUTION OCCURS AT THE TIME OF DISEASE PROGRESSION DURING IBRUTINIB THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY CLL. | Philip Thompson | ![]() |
![]() |
|||
241-P | LANDSCAPE OF SOMATIC MUTATIONS AND THEIR IMPACT ON RESPONSE AND OUTCOMES FROM LENALIDOMIDE-BASED THERAPIES IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) | Boyu Hu | ![]() |
![]() |
|||
242-P | HIGH THROUGHPUT IMMUNOPROFILING OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS ASSIGNED TO STEREOTYPED SUBSET #4: NOVEL INSIGHTS INTO THE DEPTH, DIVERSITY AND TEMPORAL DYNAMICS OF CLONAL EVOLUTION | Lesley Sutton | ![]() |
![]() |
|||
243-P | FAILED HYDROXYMETHYLATION CONTRIBUTES TO A CHRONIC LYMPHOCYTIC LEUKEMIA SPECIFIC EPIGENOTYPE | Katarzyna Szarc Vel Szic | ![]() |
![]() |
|||
244-P | DNA METHYLATION PROFILING IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS CARRYING STEREOTYPED B-CELL RECEPTORS: A DIFFERENT CELLULAR ORIGIN FOR SUBSET #2? | Sujata Bhoi | ![]() |
![]() |
|||
245-P | ADDING OBINUTUZUMAB TO IBRUTINIB ENHANCES DEPLETION OF CLL CELLS IN PERIPHERAL BLOOD AND BONE MARROW AFTER 1 & 6 MONTHS COMBINED THERAPY INITIAL RESULTS FROM THE BLOODWISE TAP ICICLLE EXTENSION STUDY | Andrew Rawstron | ![]() |
![]() |
|||
246-P | CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS EXPRESSING THE LIGHT CHAIN IGLV3-21 HAVE A POOR PROGNOSIS INDEPENDENTLY OF HEAVY CHAIN IGHV3-21 OR THE IGHV MUTATIONAL STATUS | Basile Stamatopoulos | ![]() |
![]() |
|||
249-P | RESULTS OF A PHASE II MULTICENTER STUDY OF OBINUTUZUMAB PLUS BENDAMUSTINE IN PTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) | Alexey Danilov | ![]() |
![]() |
|||
250-P | RELATIVE SURVIVAL REACHES A PLATEAU IN HAIRY CELL LEUKEMIA (HCL): A POPULATION-BASED STUDY ON INCIDENCE, PRIMARY TREATMENT AND SURVIVAL AMONG 1,427 PATIENTS DIAGNOSED IN THE NETHERLANDS, 1989-2014 | Avinash Dinmohamed | ![]() |
![]() |
|||
251-P | CUMULATIVE ILLNESS RATING SCALE (CIRS) PROVIDES PROGNOSTIC INFORMATION BEYOND THE INTERNATIONAL PROGNOSTIC INDEX FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL-IPI): AN ACROSS-TRIAL ANALYSIS BY THE GCLLSG | Valentin Goede | ![]() |
![]() |
|||
252-P | A PHASE II RANDOMISED STUDY INVESTIGATING THE EFFICACY OF STANDARD OR HIGH-DOSE OFATUMUMAB IN COMBINATION WITH CHEMOTHERAPY IN RELAPSED CHRONIC LYMPHOCYTIC LEUKAEMIA | David Allsup | ![]() |
![]() |
|||
253-P | FINAL RESULTS OF THE PHASE IB GALTON TRIAL IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): DURABLE REMISSIONS WITH FRONTLINE OBINUTUZUMAB (G) PLUS FLUDARABINE/CYCLOPHOSPHAMIDE (G-FC) OR BENDAMUSTINE (G-B) | Jennifer Brown | ![]() |
![]() |
|||
254-P | THE PROGNOSTIC SIGNIFICANCE OF CLL-IPI AFTER REDUCED INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANT IN CHRONIC LYMPHOCYTIC LEUKEMIA: THE MAYO CLINIC EXPERIENCE | Theodora Anagnostou | ![]() |
![]() |
|||
255-P | IMPACT OF ABCG2, OCT1 AND ABCB1 (MDR1) ON TREATMENT FREE REMISSION IN AN EUROSKI SUBTRIAL | Sébastien Rinaldetti | ![]() |
![]() |
|||
256-P | HLA-G MOLECULES AND CLINICAL OUTCOME IN CHRONIC MYELOID LEUKEMIA | Giovanni Caocci | ![]() |
![]() |
|||
257-P | DURABLE TREATMENT-FREE REMISSION (TFR) AFTER STOPPING SECOND-LINE NILOTINIB (NIL) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): ENESTOP 96-WK UPDATE | Timothy Hughes | ![]() |
![]() |
|||
258-P | NILOTINIB-INDUCED METABOLIC DYSFUNCTION: INSIGHTS FROM A TRANSLATIONAL PILOT STUDY USING IN VITRO ADIPOCYTE MODELS AND PATIENT COHORTS | Sudeep Pushpakom | ![]() |
![]() |
|||
259-P | EARLY PREDICTION OF THE MOLECULAR RESPONSE TO BCR-ABL1 TYROSINE KINASE INHIBITORS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA | Su Young Jung | ![]() |
![]() |
|||
261-P | A HIGH SENSITIVITY HIGH SPECIFICITY DIGITAL PCR ASSAY FOR BCR-ABL | Georg-Nikolaus Franke | ![]() |
![]() |
|||
262-P | VALIDATION OF THE EUTOS LONG TERM SURVIVAL (ELTS) SCORE IN DUTCH CML-PATIENTS | Inge Geelen | ![]() |
![]() |
|||
263-P | FINAL STUDY RESULTS OF DISCONTINUATION OF DASATINIB IN PATIENTS WITH CML WHO MAINTAINED DEEP MOLECULAR RESPONSE FOR LONGER THAN ONE YEAR (DADI TRIAL) AFTER THREE YEARS OF FOLLOW-UP | Hirohisa Nakamae | ![]() |
![]() |
|||
264-P | ACUTE MYELOID LEUKEMIA ALTERS THE PERMEABILITY OF THE BONE MARROW VASCULAR MICROENVIRONMENT, FOSTERING DISEASE PROGRESSION AND DRUG RESISTANCE | Diana Passaro | ![]() |
![]() |
|||
265-P | BUILDING HUMAN BONE MARROW-LIKE MODELS TO STUDY NICHE INTERACTIONS | Richard Groen | ![]() |
![]() |
|||
267-P | TEMPLATED V(D)J INSERTIONS ARE A NOVEL BIOLOGIC MECHANISM FOR B-CELL RECEPTOR REPERTOIRE DIVERSIFICATION | Marvyn Koning | ![]() |
![]() |
|||
268-P | TARGETING THE CASPASE / NOX2 AXIS TO MODULATE MACROPHAGE POLARIZATION | Stéphanie Solier | ![]() |
![]() |
|||
269-P | MULTIPLE MYELOMA-POLARIZED M2C MACROPHAGES PROMOTE A TUMOR-SUPPORTIVE OSTEOLYTIC MICROENVIRONMENT VIA CXCL13 | Katia Beider | ![]() |
![]() |
|||
270-P | RE-ORDERING THE B CELL DEVELOPMENT HIERARCHY IN HUMAN FETAL BONE MARROW: CHARACTERISATION OF A NOVEL HUMAN FETAL B PROGENITOR | Sorcha O´Byrne | ![]() |
![]() |
|||
271-P | HUNDREDS OF EMBRYONIC HEMATOPOIETIC PRECURSORS CONTRIBUTE TO LIFE-LONG HEMATOPOIESIS | Miguel Ganuza Fernandez | ![]() |
![]() |
|||
272-P | A20 RESTRAINS THYMIC REGULATORY T CELL DEVELOPMENT | Tobias Haas | ![]() |
![]() |
|||
273-P | THE TRANSCRIPTION FACTOR C/EBPG REGULATES MAST CELL DEVELOPMENT AND FUNCTION | Miroslava Kardosova | ![]() |
![]() |
|||
274-P | TRANSCRIPTIONAL DIVERSITY AND DEVELOPMENTAL POTENTIAL OF EARLY HEMATOPOIETIC PROGENITORS REVEALED BY CELLULAR BARCODING AND TRANSCRIPTOME-WIDE PROFILING | Diana Tronik-Le Roux | ![]() |
![]() |
|||
275-P | LONG-TERM OUTCOME OF PATIENTS WITH NODULAR LYMPHOCYTE-PREDOMINANT HODGKIN LYMPHOMA (NLPHL) TREATED WITHIN THE RANDOMIZED HD7-HD15 TRIALS: AN ANALYSIS FROM THE GERMAN HODGKIN STUDY GROUP (GHSG) | Dennis Eichenauer | ![]() |
![]() |
|||
276-P | ADVANCED HODGKIN LYMPHOMA IN THE EAST OF ENGLAND CANCER NETWORK: A 10-YEAR COMPARATIVE ANALYSIS OF OUTCOMES FOR ABVD AND ESCALATED-BEACOPP TREATED PATIENTS AGED 16–59 | James Russell | ![]() |
![]() |
|||
277-P | IMPACT ON SURVIVAL OF EARLY DETECTION OF RECURRENCE IN THE FOLLOW-UP OF HIGH RISK HODGKIN LYMPHOMA IN FIRST COMPLETE REMISSION | Novella Pugliese | ![]() |
![]() |
|||
278-P | LATER LINE DRUG TREATMENT PATTERNS OF CLASSICAL HODGKIN´S LYMPHOMA (CHL) PATIENTS IN CANADA, FRANCE, GERMANY AND THE UNITED KINGDOM | Katherine Byrne | ![]() |
![]() |
|||
279-P | CHEMOTHERAPY AND RADIATION IMPROVE SURVIVAL IN EARLY STAGE CLASSICAL HODGKIN LYMPHOMA, A STATEWIDE CANCER REGISTRY ANALYSIS. | Hayder Saeed | ![]() |
![]() |
|||
280-P | THE IMPACT OF TREATMENT WITH BRENTUXIMAB VEDOTIN ON OVERALL SURVIVAL OF PATIENTS WITH HODGKIN LYMPHOMA RELAPSED AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION. A NATIONWIDE POPULATION BASED ANALYSIS | Panagiotis Tsirigotis | ![]() |
![]() |
|||
281-P | NIVOLUMAB FOR RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: EXPERIENCE IN TURKEY | Burhan Ferhanoglu | ![]() |
![]() |
|||
283-P | FDG PET-CT MAYBE A USEFUL TOOL TO IDENTIFY DOXORUBICIN INDUCED CARDIOTOXICITY IN HODGKIN LYMPHOMA | Gianmario Sambuceti | ![]() |
![]() |
|||
284-P | ELEVATED SYSTEMIC HEME AND IRON LEVELS AS RISK FACTORS FOR VASCULAR DYSFUNCTION AND ATHEROSCLEROSIS: EVIDENCE FROM B-THALASSEMIA AND HEMOCHROMATOSIS COHORT STUDIES | Francesca Vinchi | ![]() |
![]() |
|||
287-P | ASSESSMENT OF THE PERFORMANCE OF A WIDELY AVAILABLE T2*/R2* LIVER IRON CONCENTRATION METHOD USED IN CLINICAL PRACTICE IN A POPULATION OF THALASSEMIA PATIENTS | Tim St Pierre | ![]() |
![]() |
|||
289-P | WHEN IRON LEADS TO RED CELLS (AND VICE VERSA): A COMPREHENSIVE PHENOTYPE -TOWARDS NGS/WES PATHWAY FOR THE DIAGNOSIS OF RED CELL AND IRON DISORDERS | Patricia Aguilar Martinez | ![]() |
![]() |
|||
290-P | CHANGES IN LIVER IRON CONCENTRATION R2 MRI MEASUREMENT ACROSS DIFFERENT CHELATION REGIMENS IN PATIENTS WITH HEMATOLOGICAL DISORDERS: REAL-LIFE EXPERIENCE FROM LICNET | Aurelio Maggio | ![]() |
![]() |
|||
291-P | IN UTERO IRON STATUS AND AUDITORY NEURAL MATURATION IN FULL TERM INFANTS BORN TO MOTHERS WITH IRON DEFICIENCY ANEMIA | Rania El-Farrash | ![]() |
![]() |
|||
292-P | THE RELATIONSHIP BETWEEN SERUM FERRITIN AND LIVER IRON CONCENTRATION IN PEDIATRIC CANCER SURVIVORS | Tim St Pierre | ![]() |
![]() |
|||
293-P | DECREASED MCP-1 LEVELS IN PATIENTS WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA: A CYTOKINE SIGNATURE OF IRON DEFICIENCY | Graça Porto | ![]() |
![]() |
|||
295-P | GENOME-WIDE ASSOCIATION STUDY OF HODGKIN LYMPHOMA IDENTIFIES HISTOLOGY-SPECIFIC ASSOCIATIONS AND TRANSCRIPTIONAL REGULATORS OF DISEASE SUSCEPTIBILITY | Amit Sud | ![]() |
![]() |
|||
296-P | SOX11 PROMOTES TUMOR PROTECTIVE MICROENVIRONMENT INTERACTIONS IN MANTLE CELL LYMPHOMA | Patricia Balsas | ![]() |
![]() |
|||
297-P | AICDA DRIVES EPIGENETIC HETEROGENEITY IN GERMINAL CENTER-DERIVED LYMPHOMAS AND ACCELERATES LYMPHOMAGENESIS | Pilar Dominguez | ![]() |
![]() |
|||
298-P | XPO1 INHIBITION SYNERGIZES WITH BCR INHIBITION, BLOCKS TUMOR GROWTH AND PROLONGS SURVIVAL IN A BIOLUMINESCENT ANIMAL MODEL OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA | Marta Crespo | ![]() |
![]() |
|||
300-P | A COMPREHENSIVE PORTRAIT OF THE DNA METHYLOME OF 866 SAMPLES FROM DIFFERENT B CELL NEOPLASMS: BIOLOGICAL INSIGHTS AND CLINICAL APPLICATIONS | Martí Duran-Ferrer | ![]() |
![]() |
|||
302-P | STAT3 IS CONSTITUTIVELY ACTIVATED AND CAN BE A THERAPEUTIC TARGET OF JAK INHIBITORS IN CHRONIC ACTIVE EPSTEIN-BARR VIRUS INFECTION | Erika Onozawa | ![]() |
![]() |
|||
303-P | RECURRENT MUTATIONS IN MICRO-RNA BINDING SITES MAY BE POTENTIALLY RELEVANT IN FOLLICULAR LYMPHOMA | Erika Larrea | ![]() |
![]() |
|||
304-P | CLINICAL IMPACT OF TP53 AND KMT2D MUTATIONS IN MCL RECEIVING HIGH-DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION: UPDATED RESULTS FROM THE FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 PHASE III TRIAL | Simone Ferrero | ![]() |
![]() |
|||
305-P | A LOOKBACK AT VWD TYPE 2A AND 2M CLASSIFICATION IN A LARGE COMPREHENSIVE HAEMOPHILIA CENTRE. | Sarah Jaafar | ![]() |
![]() |
|||
306-P | RETROSPECTIVE EVALUATION OF PHENOTYPE AND MANAGEMENT OF DYSFIBRINOGENEMIA AND HYPODYSFIBRINOGENEMIA IN A COHORT OF ITALIAN PATIENTS. | Cristina Santoro | ![]() |
![]() |
|||
308-P | PREVALENCE OF GENETIC MARKERS OF OXIDATIVE STRESS IN PATIENTS WITH SEVERE HEMOPHILIA FROM NORTH-WESTERN RUSSIA | Sergey Kapustin | ![]() |
![]() |
|||
309-P | THE ROLE OF DNA METHYLATION AND EXPRESSION OF MMP-2 AND MMP-9 IN PATHOGENESIS OF INTRACEREBRAL HEMORRHAGE IN CONGENITAL FACTOR XIII DEFICIENCY | Ali Noroozi-Aghideh | ![]() |
![]() |
|||
311-P | HPA-3A/3A GENOTYPE IS A POSSIBLE RISK FACTOR OF SEVERE HEMORRHAGIC SYNDROME IN PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA | Zotova Irina | ![]() |
![]() |
|||
312-P | AN ALGORITHM TO IDENTITY CASES OF SEVERE HEMORRHAGE IN ROUTINELY COLLECTED HEALTHCARE DATA | Aukje Kreuger | ![]() |
![]() |
|||
313-P | MOLECULAR MECHANISMS AND CLINICAL SIGNIFICANCE OF REDUCED PTPN1 EXPRESSION IN MYELODYSPLASTIC SYNDROMES | Masayuki Shiseki | ![]() |
![]() |
|||
315-P | UPDATED RESULTS FROM PHASE 2 STUDY OF GUADECITABINE FOR PATIENTS WITH UNTREATED INT-2/HIGH RISK MYELODYSPLASTIC SYNDROMES OR CHRONIC MYELOMONOCYTIC LEUKEMIA | Guillermo Montalban-Bravo | ![]() |
![]() |
|||
316-P | AZACITIDINE IMPROVES OUTCOME IN HIGH RISK MDS PATIENTS WITH CHROMOSOME 7 ABNORMALITIES: RETROSPECTIVE COMPARISON OF GESMD AND GFM REGISTRIES. | María Díez Campelo | ![]() |
![]() |
|||
317-P | UN UPDATE OF A PHASE II EXPLORATORY STUDY OF OPN-305, A TOLL-LIKE RECEPTOR 2 (TLR-2) ANTIBODY, IN PATIENTS WITH LOWER RISK MYELODYSPLASTIC SYNDROMES WITH PRIOR HYPOMETHYLATING AGENT (HMA) THERAPY | Guillermo Garcia-Manero | ![]() |
![]() |
|||
318-P | IN PATIENTS UNDEGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MDS DEVELOPMENT OF CHRONIC GVHD COULD AMELIORATE THE ADVERSE IMPACT OF SPECIFIC SOMATIC MUTATIONS | Juan-Carlos Caballero Berrocal | ![]() |
![]() |
|||
319-P | VOSAROXIN PLUS AZACITIDINE TREATMENT FOR PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS): A PHASE 1/COHORT EXPANSION STUDY | Meagan Jacoby | ![]() |
![]() |
|||
320-P | ADVANCED STAGE MYELOMA IS CHARACTERIZED BY A SIGNIFICANT INCREASE OF MUTATIONS IN GENES ASSOCIATED WITH DRUG RESPONSE | Santiago Barrio | ![]() |
![]() |
|||
321-P | ILF2-YB1 INTERACTION MODULATES RNA SPLICING TO INDUCE RESISTANCE TO DNA-DAMAGING AGENTS IN 1Q21-AMPLIFIED MULTIPLE MYELOMA | Matteo Marchesini | ![]() |
![]() |
|||
322-P | PROGNOSTIC IMPLICATION OF SOMATIC MUTATIONS BY NEXT GENERATION SEQUENCING: AN ANALYSIS FROM THE MMRF COMMPASS STUDY IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS. | Mattia D´agostino | ![]() |
![]() |
|||
323-P | TARGETING GENE DEPENDENCY OF 1Q AMPLIFICATION IN MULTIPLE MYELOMA | Salomon Manier | ![]() |
![]() |
|||
324-P | DUAL INHIBITION OF DNMT1 AND EZH2 CAN EFFECTIVELY OVERCOME BOTH INTRINSIC AND ACQUIRED RESISTANCE OF MYELOMA CELLS TO IMIDS | Konstantinos Dimopoulos | ![]() |
![]() |
|||
325-P | MULTILAYER EPIGENOMIC ANALYSES REVEAL OF NEW CANDIDATE ONCOGENES INVOLVED IN THE PATHOGENESIS OF MULTIPLE MYELOMA | Raquel Ordoñez | ![]() |
![]() |
|||
327-P | PATHOPHYSIOLOGICAL FUNCTIONS AND CLINICAL IMPACT OF THE NEW IMMUNORECEPTOR SLAMF3 IN MULTIPLE MYELOMA | Mariko Ishibashi | ![]() |
![]() |
|||
328-P | TARGETING CD74 IN MULTIPLE MYELOMA WITH A NOVEL ANTIBODY DRUG CONJUGATE (ADC), STRO-001 | Arturo Molina | ![]() |
![]() |
|||
329-P | GENOTYPE CHARACTERIZATION OF LIGHT CHAIN AMYLOIDOSIS BY WHOLE EXOME SEQUENCING | Isabel Cuenca | ![]() |
![]() |
|||
330-P | IMPROVED SURVIVAL IN 21,465 MULTIPLE MYELOMA PATIENTS: RESULTS FROM A POPULATION-BASED STUDY | Sigrun Thorsteinsdottir | ![]() |
![]() |
|||
331-P | PROGNOSTIC IMPLICATIONS OF MULTIPLE CYTOGENETIC HIGH-RISK ABNORMALITIES IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA | Moritz Binder | ![]() |
![]() |
|||
332-P | LENALIDOMIDE MAINTENANCE VS PLACEBO AFTER STEM CELL TRANSPLANT FOR PATIENTS WITH MULTIPLE MYELOMA: OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL AFTER ADJUSTING FOR TREATMENT CROSSOVER IN CALGB | Philip McCarthy | ![]() |
![]() |
|||
334-P | EFFICACY AND SAFETY OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (DRD) VERSUS RD ALONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED ANALYSIS OF POLLUX | Meletios Dimopoulos | ![]() |
![]() |
|||
335-P | DARATUMUMAB-BASED COMBINATION REGIMENS IN ELDERLY (=75 YEARS) PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): SUBGROUP ANALYSIS OF THE PHASE 3 CASTOR AND POLLUX STUDIES | Maria-Victoria Mateos | ![]() |
![]() |
|||
337-P | EVALUATION OF GROWTH DIFFERENTIATION FACTOR-1 (GDF15) AS A NEW BIOMARKER FOR RENAL OUTCOMES IN DIFFERENT COHORTS OF PATIENTS WITH LIGHT CHAIN (AL) AMYLOIDOSIS | Efstathios Kastritis | ![]() |
![]() |
|||
338-P | AN OPEN-LABEL, PHASE 2 STUDY TO EVALUATE THE ORAL COMBINATION OF IXAZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (ICD) IN TRANSPLANT-INELIGIBLE PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) | Meletios Dimopoulos | ![]() |
![]() |
|||
339-P | THE ORAL PROTEASOME INHIBITOR IXAZOMIB IN COMBINATION WITH MELPHALAN-PREDNISONE (MP) FOR PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): PHASE 1/2 DOSE-ESCALATION STUDY (NCT01335685) | Jesus San Miguel | ![]() |
![]() |
|||
340-P | FEASIBILITY AND EFFICACY OF DOSE ADJUSTED MELPHALAN – PREDNISONE – BORTEZOMIB (MPV) IN PATIENTS = 75 YEARS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; PRELIMINARY RESULTS OF THE PHASE II HOVON 123 STUDY | Sonja Zweegman | ![]() |
![]() |
|||
342-P | CHEMOTHERAPY BEFORE AND AFTER HEART TRANSPLANTATION FOR PATIENTS WITH ADVANCED CARDIAC AL AMYLOIDOSIS, SINGLE CENTER RESULTS WITH LONG-TERM FOLLOW-UP | Ute Hegenbart | ![]() |
![]() |
|||
343-P | MM-013 PHASE 2 MULTICENTER STUDY OF POMALIDOMIDE (POM) PLUS LOW-DOSE DEXAMETHASONE (LODEX) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) AND RENAL IMPAIRMENT (RI) | Pieter Sonneveld | ![]() |
![]() |
|||
345-P | ASSESSMENT OF MOBILIZATION COST FOR MULTIPLE MYELOMA USING 2 DIFFERENT STRATEGIES: HIGH-DOSE CYCLOPHOSPHAMIDE VERSUS PLERIXAFOR. ON BEHALF OF IFM. | Zoe Van De Wyngaert | ![]() |
![]() |
|||
346-P | SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS OF INDUCTION TREATMENT FOR NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS | Jin-Chul Kim | ![]() |
![]() |
|||
347-P | A STUDY OF UTILITY OR FUTILITY OF PERFORMING SKELETAL SURVEYS IN PARAPROTEINAEMIA: A MULTICENTER EXPERIENCE FROM UK | ovini gamage | ![]() |
![]() |
|||
348-P | SERUM FLC MEASUREMENTS COMPLEMENT BONE MARROW ASSESSMENT TO DETERMINE PROGNOSIS IN MYELOMA PATIENTS ACHIEVING DEEP RESPONSES | Thomas Dejoie | ![]() |
![]() |
|||
351-P | CYTOGENETIC ABNORMALITIES IN POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: CORRELATIONS WITH GENOTYPE AND PHENOTYPE IN THE MYSEC STUDY | Barbara Mora | ![]() |
![]() |
|||
352-P | MUTATIONAL LANDSCAPE OF MYELODYSPLASTIC SYNDROME/MYELOPROLIFERATIVE NEOPLASM - UNCLASSIFIABLE (MDS/MPN-U) | Prithviraj Bose | ![]() |
![]() |
|||
353-P | GENOME WIDE DNA METHYLATION PROFILING IS PREDICTIVE OF OUTCOME IN JUVENILE MYELOMONOCYTIC LEUKEMIA | Elliot Stieglitz | ![]() |
![]() |
|||
354-P | LEUKEMIC TRANSFORMATION OF MYELOPROLIFERATIVE NEOPLASMS: IS NGS PROFILE THE BEST PROGNOSTIC BIOMARKER? | Venton Geoffroy | ![]() |
![]() |
|||
355-P | INCIDENCE AND OUTCOME OF SECONDARY NON HEMATOLOGICAL CANCERS IN ADULT PATIENTS WITH MASTOCYTOSIS | Massimiliano Bonifacio | ![]() |
![]() |
|||
356-P | HIGH WBC COUNT WAS THE RISK FACTOR FOR SURVIVAL IN PATIENTS WITH CSF3R- MUTATED CHRONIC NEUTROPHILIC LEUKEMIA | Qian Jiang | ![]() |
![]() |
|||
357-P | CLINICAL PHENOTYPE AND OUTCOME OF ESSENTIAL THROMBOCYTHEMIA AND PREFIBROTIC MYELOFIBROSIS DIAGNOSED ACCORDING TO THE REVISED 2016 WHO DIAGNOSTIC CRITERIA | Elisa Rumi | ![]() |
![]() |
|||
358-P | VALIDATION OF THE REVISED IPSET-THROMBOSIS SCORE IN 734 PATIENTS WITH WHO 2016-DEFINED ESSENTIAL THROMBOCYTHEMIA. REPORT OF THE REGISTRO ITALIANO TROMBOCITEMIE (RIT) | Luigi Gugliotta | ![]() |
![]() |
|||
359-P | CORRELATIONS BETWEEN INFLAMMATORY BIOMARKERS AND INDIVIDUAL SYMPTOMS EXPRESSED BY MYELOFIBROSIS PATIENTS IN THE COMFORT-I TRIAL: ANALYSIS OF BASELINE ASSOCIATIONS AND CHANGES OVER TIME | Holly Geyer | ![]() |
![]() |
|||
360-P | NOVEL HETEROZYGOUS ITGB3 P.T746DEL MUTATION INDUCING SPONTANEOUS ACTIVATION OF INTEGRIN ?IIB?3 CAUSES AUTOSOMAL DOMINANT MACROTHROMBOCYTOPENIA WITH ABNORMAL ?IIB?3 LOCALIZATION | Naohiro Miyashita | ![]() |
![]() |
|||
361-P | CHANGES IN THE GENE EXPRESSION PROFILE OF IMMUNE THROMBOCYTOPENIA PATIENTS TREATED WITH ELTROMBOPAG | JM Bastida | ![]() |
![]() |
|||
362-P | DEFECTIVE PTEN REGULATION CONTRIBUTES TO B CELL HYPERRESPONSIVENESS IN CHRONIC IMMUNE THROMBOCYTOPENIA | shixuan Wang | ![]() |
![]() |
|||
365-P | NOVEL RUNX1 MUTATIONS IN FAMILIES WITH INHERITED THROMBOCYTOPENIA | Patrizia Noris | ![]() |
![]() |
|||
367-P | A SINGLE-ARM, OPEN-LABEL, LONG-TERM EFFICACY AND SAFETY STUDY OF SUBCUTANEOUS (SC) ROMIPLOSTIM IN CHILDREN WITH IMMUNE THROMBOCYTOPENIA (ITP) | John Grainger | ![]() |
![]() |
|||
368-P | NOVEL THIENOPYRIDINES AS POTENT PLATELET INHIBITORS: FUTURE TREATMENTS FOR PLATELET HYPERACTIVITY DISORDERS? | Naif Binsaleh | ![]() |
![]() |
|||
369-P | PATIENT-REPORTED OUTCOMES AND HEALTHCARE RESOURCE UTILIZATION BEFORE AND DURING TREATMENT WITH ECULIZUMAB: RESULTS FROM THE INTERNATIONAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA REGISTRY | Petra Muus | ![]() |
![]() |
|||
370-P | ECONOMIC IMPACT OF INTRODUCING AGE-ADJUSTED D-DIMER CUT-OFF LEVELS IN THE DIAGNOSIS STRATEGY OF VENOUS THROMBOEMBOLISM | Pierre Toulon | ![]() |
![]() |
|||
371-P | IMPACT OF CELLULAR THERAPY ON THE ECONOMIC BURDEN AND SURVIVAL FOLLOWING RELAPSE AFTER HLA IDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ACUTE LEUKEMIA AND MYELODYSPLASTIC SYNDROME. | Silvy Lachance | ![]() |
![]() |
|||
372-P | ACUTE MYELOID LEUKEMIA (AML) TREATMENT PRACTICE PATTERNS, HEALTHCARE RESOURCE UTILIZATION (HRU) AND COSTS IN A US COMMERCIALLY-INSURED POPULATION | May Hagiwara | ![]() |
![]() |
|||
374-P | ACCESS TO COMMUNITY CHEMOTHERAPY IMPROVES PATIENT QUALITY OF LIFE | Rachel Iredale | ![]() |
![]() |
|||
377-P | NUTRITIONAL NEEDS AND PREFERENCES OF MYELOPROLIFERATIVE NEOPLASM PATIENTS: PHASE IA OF THE NUTRIENT STUDY | Robyn Scherber | ![]() |
![]() |
|||
378-P | DO PHYSICIANS NEED HELP TO ADEQUATELY INFORM AND SUPPORT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA? RESULTS FROM A QUALITATIVE STUDY IN GREECE | Christina Karamanidou | ![]() |
![]() |
|||
379-P | OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH ACUTE LEUKEMIA ABOVE 70 YEARS OF AGE: ON BEHALF OF THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT | Arnon Nagler | ![]() |
![]() |
|||
380-P | BLOOD BAALC AND MN1 COPY NUMBER ASSESSMENT BY DIGITAL DROPLET PCR PRIOR TO ALLOGENEIC TRANSPLANTATION PREDICTS RELAPSE IN ACUTE MYELOID LEUKEMIA PATIENTS | Madlen Jentzsch | ![]() |
![]() |
|||
381-P | THE USE OF BPX-501 DONOR T CELL INFUSION (WITH INDUCIBLE CASPASE 9 SUICIDE GENE) TOGETHER WITH HLA-HAPLOIDENTICAL STEM CELL TRANSPLANT TO TREAT CHILDREN WITH HEMOGLOBINOPATHIES AND ERYTHROID DISORDERS | Alice Bertaina | ![]() |
![]() |
|||
382-P | EXCELLENT RESPONSE, LOW TRM AND GOOD SURVIVAL IN PATIENTS WITH THERAPY-REFRACTORY AGVHD AFTER TREATMENT WITH EQUIPOTENT MSCS OF A SERUM-FREE MSC-BANK GENERATED FROM POOLED BM-MNCS OF MULTIPLE DONORS | Peter Bader | ![]() |
![]() |
|||
383-P | HIGHER PEAK TACROLIMUS CONCENTRATIONS AFTER ALLOGENEIC TRANSPLANTATION INCREASE THE RISK OF ENDOTHELIAL CELL DAMAGE COMPLICATIONS | Takanobu Morishita | ![]() |
![]() |
|||
384-P | IMPACT OF CONDITIONING REGIMEN ON OUTCOMES OF T-REPLETE HAPLO-IDENTICAL TRANSPLANTATION FOR PATIENTS OVER 45 YEARS-OLD WITH AML: A STUDY ON BEHALF OF THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT | Daniela Nasso | ![]() |
![]() |
|||
385-P | ROLE OF UPFRONT ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH AGGRESSIVE ADULT T-CELL LEUKEMIA-LYMPHOMA: A DECISION ANALYSIS | Shigeo Fuji | ![]() |
![]() |
|||
387-P | INTERFERON-? IS EFFECTIVE FOR TREATMENT OF MINIMAL RESIDUAL DISEASE IN PATIENTS WITH ACUTE LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION | Xiao-Dong Mo | ![]() |
![]() |
|||
388-P | COMPARABLE LONG-TERM OUTCOME AFTER ALLOGENEIC STEM-CELL TRANSPLANTATION FOR OLDER PATIENTS (AGE =50 YEARS) WITH AML FROM SIBLING AND MATCHED UNRELATED DONORS. A REPORT ON BEHALF OF THE ALWP OF EBMT. | Avichai Shimoni | ![]() |
![]() |
|||
389-P | IMPACT OF AZACITIDINE PRETREATMENT ON OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH HIGH-RISK MYELODYSPLASTIC SYNDROME | Jun Aoki | ![]() |
![]() |
|||
390-P | LOW-DOSE DECITABINE IMPROVES PLATELET RECOVERY IN PATIENTS WITH ISOLATED THROMBOCYTOPENIA AFTER HSCT | Yue Han | ![]() |
![]() |
|||
391-P | QUANTITATIVE PROTEOMICS OF PLASMA EXTRACELLULAR VESICLES TO IDENTIFY NOVEL BIOMARKERS OF CLINICAL SEVERITY FOR HBE/?-THALASSEMIC PATIENTS | Janejira Kittivorapart | ![]() |
![]() |
|||
392-P | A SELECTIVE ORAL GLYT1 INHIBITOR IMPROVES ANEMIA IN A MOUSE MODEL OF BETA-THALASSEMIA | Lucia De Franceschi | ![]() |
![]() |
|||
393-P | MAY MUTATIONS IN THE KLF1 GENE HAVE WORSENING EFFECTS ON THE BETA THALASSEMIA PHENOTYPE? | Michela Grosso | ![]() |
![]() |
|||
394-P | SECONDARY SOLID TUMORS FOLLOWING HEMATOPOIETIC CELL TRANSPLANTATION FOR THALASSEMIA MAJOR | Antonella Meloni | ![]() |
![]() |
|||
395-P | VALIDATING A NOVEL CAPILLARY ELECTROPHORESIS: THE MOST SUITABLE PLATFORM FOR THE NATIONAL NEWBORN SCREENING PROGRAM IN A REGION WITH HIGH PREVALENCE OF THALASSEMIA AND HEMOGLOBINOPATHIES | Thidarat Suksangpleng | ![]() |
![]() |
|||
397-P | INCREASING INCIDENCE OF MALIGNACIES IN AGING THALASSEMIC PATIENTS: A SINGLE INSTITUTION´S LONGITUDINAL EXPERIENCE | Elpida Repousi | ![]() |
![]() |
|||
398-P | SAFETY AND EFFICACY OF EARLY START WITH SUBOPTIMAL DOSE OF DEFERIPRONE IN MINIMALLY TRANSFUSED INFANTS WITH TRANSFUSION DEPENDENT THALASSEMIA: A RANDOMIZED TRIAL | Mohsen Elalfy | ![]() |
![]() |
|||
399-P | LONGITUDINAL PROSPECTIVE MRI STUDY IN PEDIATRIC PATIENTS WITH THALASSEMIA MAJOR | Maddalena Casale | ![]() |
![]() |
|||
400-P | LONG TERM FOLLOW-UP OF A COHORT OF WELL TREATED ?-THALASSEMIA MAJOR PATIENTS BY MULTI-ORGAN R2* MAGNETIC RESONANCE IMAGING | GianLuca Forni | ![]() |
![]() |
|||
401-P | DEVELOPMENT OF HTLV-1 HYPERIMMUNE GLOBULINS AGAINST HTLV-1 INFECTION | Takuo Mizukami | ![]() |
![]() |
|||
402-P | THE CONTAMINATION OF TUMOR CELLS IN THE APHERESIS MATERIAL DOES NOT PREDICT THE RESPONSE OF MULTIPLE MYELOMA PATIENTS TO AUTOLOGOUS TRANSPLANTATION | Maria Luisa Lozano | ![]() |
![]() |
|||
403-P | EVALUATION OF THERAPEUTIC PLASMA EXCHANGE AT A TERTIARY LONDON HOSPITAL | Rachel Moll | ![]() |
![]() |
|||
404-P | A COMPREHENSIVE PROTEOMICS STUDY ON PLATELET CONCENTRATES: PLATELET PROTEOME, STORAGE TIME AND MIRASOL PATHOGEN REDUCTION TECHNOLOGY | Laura Gutierrez | ![]() |
![]() |
|||
405-P | USE OF A SURVEY TO ASSESS AND IMPROVE ADHERENCE TO UK BLOOD TRANSFUSION GUIDELINES IN A HOSPITAL SETTING | Dana Warcel | ![]() |
![]() |
|||
406-P | SCREENING OF TRANSFUSION PRODUCTS FOR PRION DISEASES USING APTAMERS AND TUNABLE RESISTIVE PULSE SENSING | Matthew Healey | ![]() |
![]() |
|||
506-P | T CELL EXHAUSTION CHARACTERIZED BY COMPROMISED MHC CLASS I AND II RESTRICTED CYTOTOXIC ACTIVITY ASSOCIATES WITH ACUTE B LYMPHOBLASTIC LEUKEMIA RELAPSE AFTER ALLO-HSCT | Long Liu | ![]() |
![]() |
|||
507-P | RUXOLITINIB/NILOTINIB COTREATMENT BETTER INHIBITS LEUKEMIA-PROPAGATING CELLS IN PHILADELPHIA CHROMOSOME-POSITIVE ALL | Yuan Kong | ![]() |
![]() |
|||
509-P | CD45RA- MEMORY T CELLS EXPRESSING AN NKG2D-CAR TARGET PEDIATRIC ACUTE LEUKEMIA | Lucia Fernandez | ![]() |
![]() |
|||
510-P | A BILINEAL ACUTE LYMPHOBLASTIC LEUKEMIA ORIGINATING AT A COMMON LYMPHOID PROGENITOR | Africa Gonzalez-Murillo | ![]() |
![]() |
|||
512-P | THERAPEUTIC TARGETING OF PRE-B CELL RECEPTOR SIGNALLING IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA | Ali Alhammer | ![]() |
![]() |
|||
513-P | BMP-4 LEVELS IN CHILDHOOD B-ALL OF LOW-/INTERMEDIATE-RISK GROUPS IDENTIFY CHILDREN WITH POOR OUTCOME | Lidia Fernández-Sevilla | ![]() |
![]() |
|||
514-P | TARGETING LOCALIZATION OF THE IL-7 RECEPTOR WITHIN LIPID RAFTS AS A THERAPEUTIC STRATEGY FOR T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | Anne Buffière | ![]() |
![]() |
|||
515-P | SYSTEMATIC MRI SCREENING IDENTIFIES EXTENSIVE ASYMPTOMATIC OSTEONECROTIC LESIONS IN ADOLESCENTS WITH ALL - FIRST INTERIM FINDINGS OF THE OPAL TRIAL | Michaela Kuhlen | ![]() |
![]() |
|||
516-P | FINAL ANALYSIS OF A RANDOMIZED STUDY COMPARING PROPHYLACTIC AND MRD-TRIGGERED, PRE-EMPTIVE IMATINIB AFTER HSCT FOR PH+/BCR-ABL1 POSITIVE ALL: LONG-TERM PATIENT OUTCOME AND IMPLICATIONS OF MRD ANALYSIS | Fabian Lang | ![]() |
![]() |
|||
518-P | UPDATED RESULTS OF A PHASE II STUDY OF HYPER-CVAD PLUS PONATINIB AS FRONTLINE THERAPY FOR ADULTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA | Nicholas Short | ![]() |
![]() |
|||
520-P | A PHASE II STUDY WITH A SEQUENTIAL CLOFARABINE-CYCLOPHOSPHAMIDE COMBINATION SCHEDULE AS SALVAGE THERAPY FOR REFRACTORY AND RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA (R/R ALL) IN ADULT PATIENTS | Renato Bassan | ![]() |
![]() |
|||
526-P | DESIGNING THE NEXT GENERATION CD33-TARGETING ADC: IMGN779, SELECTED FOR POTENCY, NOVEL MECHANISM AND PRECLINICAL TOLERABILITY, WITH HIGH ACTIVITY IN DISSEMINATED AML MODELS AND MULTI-DOSE REGIMENS | Sharlene Adams | ![]() |
![]() |
|||
528-P | PKC EPSILON SUPPORTS ACUTE MYELOID LEUKEMIA BY MAINTAINING MITOCHONDRIAL REDOX HOMEOSTASIS. | Daniela Di Marcantonio | ![]() |
![]() |
|||
530-P | ROLE OF SHP2 IN A MOUSE MODEL OF AML CARRYING FLT3-ITD ALONG WITH LOSS OF TET2 | Ruchi Pandey | ![]() |
![]() |
|||
531-P | CLUSTER REGULATION OF RUNX FAMILY BY "GENE SWITCH" TRIGGERS A PROFOUND TUMOR REGRESSION OF DIVERSE ORIGINS. | Ken Morita | ![]() |
![]() |
|||
532-P | PHOSPHOPROTEOMICS AND MASS CYTOMETRY SIGNATURES OF PRIMARY AML CELL DIFFERENTIATION ARE ASSOCIATED WITH SENSITIVITY TO KINASE INHIBITORS | Pedro Casado-Izquierdo | ![]() |
![]() |
|||
534-P | GFI1B – A NOVEL ONCOSUPPRESSOR WHICH RESTRICTS NUMBER OF LEUKEMIC STEM CELLS | Aniththa Thivakaran | ![]() |
![]() |
|||
535-P | VARIANT ALLELE FREQUENCY KINETICS OF TYROSINE KINASE GENE MUTATIONS IN CORE-BINDING FACTOR ACUTE MYELOID LEUKEMIA (CBF-AML) UNDER TREATMENT WITH AND WITHOUT DASATINIB | Mridul Agrawal | ![]() |
![]() |
|||
536-P | P38? MAPK INTERACTS WITH SET REGULATING ITS INHIBITORY EFFECT ON PP2A ACTIVITY IN ACUTE MYELOID LEUKEMIA | Elena Arriazu | ![]() |
![]() |
|||
539-P | EXPLORING THE IMPACT OF LOSS OF FUNCTION STAG2 MUTATIONS ON CHROMATIN ARCHITETCURE IN MDS/AML | James Smith | ![]() |
![]() |
|||
540-P | NEXT GENERATION SEQUENCING TECHNIQUES REVEAL MOLECULAR MECHANISMS OF MYB REGULATION AND FUNCTION IN MLL-AF9 LEUKEMIA | I-Jun Lau | ![]() |
![]() |
|||
542-P | TARGETED COMBINATION THERAPY WITH CDK4/6 INHIBITOR PALBOCICLIB IN AML | Iris Uras | ![]() |
![]() |
|||
543-P | CANNABINOIDS DERIVATIVES MODIFY THE PATTERN OF SPHINGOLIPIDS IN ACUTE MYELOID LEUKEMIA CELLS AND PRODUCE A POTENT ANTI-LEUKEMIC EFFECT. | Mayte Medrano | ![]() |
![]() |
|||
544-P | PROFILING THE MUTATIONAL LANDSCAPE OF ACUTE MYELOID LEUKEMIA AT RELAPSE AFTER CHEMOTHERAPY AND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION. | Elisa Sala | ![]() |
![]() |
|||
546-P | AML PATIENTS AGED =75 YEARS ENROLLED INTO AMLCG TRIALS: DO GENETIC ALTERATIONS IMPACT CLINICAL OUTCOME IN VERY OLD, INTENSIVELY TREATED PATIENTS? | Victoria Prassek | ![]() |
![]() |
|||
548-P | BST 236, A NOVEL CYTARABINE PRO-DRUG ALLOW, FOR THE FIRST TIME, THE DELIVERY OF HIGH CYTARABINE DOSES FOR OLDER OR UNFIT PATIENTS WITH ACUTE LEUKEMIA. RESULTS OF AN ONGOING PHASE I/IIA STUDY | Tsila Zuckerman | ![]() |
![]() |
|||
549-P | FEASIBILITY AND BENEFIT OF TARGETED RNA SEQUENCING FOR THE DETECTION OF RECURRENT FUSION TRANSCRIPTS AND THE IDENTIFICATION OF NOVEL FUSION TRANSCRIPTS IN MYELOID MALIGNANCIES | Claudia Haferlach | ![]() |
![]() |
|||
550-P | COMPREHENSIVE MOLECULAR ANALYSIS OF ADULT MIXED PHENOTYPE ACUTE LEUKEMIA (MPAL) | Kiyomi Morita | ![]() |
![]() |
|||
552-P | VARIANT FLT3 MUTATIONS CAN BE ERADICATED BY CYTARABINE/ANTHRACYCLINE/CRENOLANIB INDUCTION IN ADULT PATIENTS WITH NEWLY DIAGNOSED FLT3 (ITD/TKD) MUTANT AML | Eunice Wang | ![]() |
![]() |
|||
553-P | PATIENTS WITH ACUTE MYELOID LEUKEMIA WHO HAVE MUTATIONS IN IDH1 OR IDH2 RESPOND WELL TO INDUCTION CHEMOTHERAPY WITH "7+3" DESPITE THE PRESENCE OF COMPLEX KARYOTYPE OR FLT3-ITD | Medhavi Gupta | ![]() |
![]() |
|||
554-P | VALIDATION OF PRECISION MEDICINE TEST FOR ACUTE MYELOID LEUKEMIA IN AN OBSERVATIONAL CLINICAL TRIAL. | Joan Ballesteros | ![]() |
![]() |
|||
555-P | RESPONSE-ADAPTED AZACITIDINE AND INDUCTION CHEMOTHERAPY IN PATIENTS > 60 YEARS OLD WITH NEWLY DIAGNOSED AML ELIGIBLE FOR CHEMOTHERAPY: RESULTS OF THE DRKS00004519 STUDY OF THE EAST GERMAN STUDY GROUP | Nadja Jaekel | ![]() |
![]() |
|||
556-P | OVERALL SURVIVAL WITH CPX-351 VERSUS 7+3 IN OLDER ADULTS WITH NEWLY DIAGNOSED, THERAPY-RELATED ACUTE MYELOID LEUKEMIA: SUBGROUP ANALYSIS OF A PHASE 3 STUDY | Jeffrey Lancet | ![]() |
![]() |
|||
557-P | HYPERFERRITINEMIA IS AN INDEPENDENT POOR PROGNOSTIC FACTOR IN ACUTE MYELOID LEUKEMIA | Sarah Bertoli | ![]() |
![]() |
|||
559-P | PROGNOSTIC VALUE OF EARLY WT 1 RESPONSE IN AML PATIENTS UNDERGOING INTENSIVE CHEMOTHERAPY | Sigrid Machherndl-Spandl | ![]() |
![]() |
|||
565-P | WHOLE BODY DIFFUSION-WEIGHTED MAGNETIC RESONANCE IMAGING IS A GOOD PREDICTOR OF TREATMENT OUTCOME AFTER ONE CYCLE OF IMMUNOCHEMOTHERAPY IN AGGRESSIVE LYMPHOMA | Katja De Paepe | ![]() |
![]() |
|||
567-P | PREVALENCE AND PROGNOSTIC VALUE OF MYD88 AND CD79B MUTATIONS IN IMMUNE-PRIVILEGED SITE AND (EXTRA)NODAL DLBCLS. | Joost Vermaat | ![]() |
![]() |
|||
568-P | HIV-INFECTED PATIENTS WITH RELAPSED NON-HODGKIN LYMPHOMA (NHL) OR HODGKIN LYMPHOMA (HL): RESULTS FROM THE GERMAN HIV-RELATED LYMPHOMA COHORT STUDY | Marcus Hentrich | ![]() |
![]() |
|||
569-P | RISK STRATIFICATION BASED ON NCCN-IPI AT THE TIME OF DIAGNOSIS IN COMBINATION WITH POST-TREATMENT PET-CT SCAN FOR THE TREATMENT OF NODAL PERIPHERAL T-CELL LYMPHOMA | Deok-Hwan Yang | ![]() |
![]() |
|||
570-P | LONG-TERM EFFICACY AND SAFETY OF CRIZOTINIB IN RELAPSED ALK POSITIVE LYMPHOMA PATIENTS: CLINICAL AND BIOLOGICAL CORRELATES. | Francesca Farina | ![]() |
![]() |
|||
571-P | PRELIMINARY RESULTS FROM AN OPEN-LABEL, PHASE II STUDY OF TIPIFARNIB IN RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA. | Thomas Witzig | ![]() |
![]() |
|||
572-P | BAM CONDITIONING BEFORE AUTOLOGOUS STEM CELL TRANSPLANTATION FOR LYMPHOMA: A RETROSPECTIVE STUDY ON BEHALF OF THE FRANCOPHONE SOCIETY OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY (SFGM-TC). | Jérôme Cornillon | ![]() |
![]() |
|||
573-P | ANALYSIS OF MICRORNAOME, PROTEOME AND METABOLOME OF EXOSOMES FROM PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA | Irene Martínez | ![]() |
![]() |
|||
575-P | SEVERE CHRONIC NEUTROPENIA: THE ROLE OF PRIMARY IMMUNODEFICIENCY AS CAUSATIVE AGENTS . A SINGLE CENTER DATA | Francesca Fioredda | ![]() |
![]() |
|||
576-P | TREATMENT WITH HORSE-DERIVED ANTI-THYMOCYTE GLOBULIN LEADS TO ENDURING HEMATOLOGICAL RESPONSES AND A 1.5-YEAR SURVIVAL PROBABILITY OF 87% IN ADULT ACQUIRED APLASTIC ANEMIA PATIENTS IN THE NETHERLANDS | Stijn Halkes | ![]() |
![]() |
|||
577-P | IMMUNE RECONSTITUTION IN PATIENTS WITH ACQUIRED SEVERE APLASTIC ANEMIA AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION | Xuying Pei | ![]() |
![]() |
|||
578-P | DEVELOPMENT OF A SCREENING AND DIAGNOSTIC ALGORITHM FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA USING A MODIFIED DELPHI PANEL METHODOLOGY | Alexander Röth | ![]() |
![]() |
|||
579-P | DIAMOND-BLACKFAN ANEMIA IN THE NETHERLANDS: AN OVERVIEW OF CLINICAL CHARACTERISTICS AND UNDERLYING MOLECULAR DEFECTS. | Birgit Van Dooijeweert | ![]() |
![]() |
|||
580-P | NEXT GENERATION SEQUENCING IN BONE MARROW FAILURE SYNDROMES | Eva Galvez | ![]() |
![]() |
|||
581-P | APLASTIC ANEMIA PATIENTS WITH MONOCYTE-DOMINANT PNH CLONES HAVE A UNIQUE PRESENTATION AND ARE LESS RESPONSIVE TO IMMUNOSUPPRESSIVE THERAPY | Emilie Nevill | ![]() |
![]() |
|||
582-P | RESPONSE TO ANTI-THYMOCYTE GLOBULIN (ATG) IN PATIENTS WITH APLASTIC ANEMIA (AA): A SINGLE-CENTRE EXPERIENCE OVER THE LAST 28 YEARS | Maren Oelmüller | ![]() |
![]() |
|||
583-P | NOTCH1 MUTATED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS ARE CHARACTERIZED BY A MYC-RELATED OVEREXPRESSION OF NUCLEOPHOSMIN-1 AND RIBOSOME ASSOCIATED COMPONENTS | Federico Pozzo | ![]() |
![]() |
|||
584-P | CLL-LIKE B-CELL CLONES FROM MBLLO INDIVIDUALS PERSIST AT INCREASED COUNTS AFTER SEVEN YEARS OF FOLLOW-UP. | Ignacio Criado | ![]() |
![]() |
|||
585-P | NUCLEAR LAMINA REGULATES SOMATIC HYPERMUTATION AND PROGRESSION OF B CELL MALIGNANCIES | Andrejs Braun | ![]() |
![]() |
|||
586-P | MICROENVIRONMENT REGULATION OF PROGRAMMED DEATH-1 (PD1) RECEPTOR AND ITS LIGANDS PDL1 AND PDL2 IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) | Fortunato Morabito | ![]() |
![]() |
|||
587-P | IL-4 INCREASES EXPRESSION OF POSITIVE REGULATORS OF BCR SIGNALLING IN CLL WHICH CAN BE OVERCOME BY CERDULATINIB | Matthew Blunt | ![]() |
![]() |
|||
588-P | INSIDE-OUT VLA-4 INTEGRIN ACTIVATION IS MAINTAINED IN IBRUTINIB-TREATED CHRONIC LYMPHOCYTIC LEUKEMIA EXPRESSING CD49D: CLINICAL RELEVANCE | Erika Tissino | ![]() |
![]() |
|||
589-P | IBRUTINIB RESULTS IN REDUCTION OF PHOSPHORYLATION OF MULTIPLE KINASES IN THE B-CELL RECEPTOR PATHWAY IN CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL): RESULTS OF THE BLOODWISE TAP ICICLLE STUDY | Talha Munir | ![]() |
![]() |
|||
590-P | EVALUATION OF COMBINATIONAL THERAPIES FOR RELAPSED/REFRACTORY CLL WITH MUTATED P53 | Sean Post | ![]() |
![]() |
|||
591-P | THE DNA REPLICATION PATHWAY HAS POTENTIAL PREDICTIVE VALUE FOR TKI RESPONSE AND THERAPEUTIC INTERVENTION IN CHRONIC MYELOID LEUKAEMIA | Krishna Yalla | ![]() |
![]() |
|||
592-P | SIGNAL TRANSDUCING ADAPTOR PROTEIN-1 (STAP-1) MAINTAINS CHRONIC MYELOID LEUKEMIC STEM CELLS | Jun Toda | ![]() |
![]() |
|||
593-P | TELOMERE SHORTENING IN CD34+38- BCR-ABL POSITIVE BONE MARROW CELLS FROM NEWLY DIAGNOSED PATIENTS WITH CML CORRELATES WITH THE CLONE SIZE OF THE LEUKEMIC STEM CELL COMPARTMENT | Anne-Sophie Bouillon | ![]() |
![]() |
|||
595-P | INCREASED INDOLEAMINE 2,3-DIOXYGENASE (IDO1) ACTIVITY IN EARLY CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA (CML-CP) IS REDUCED BY NILOTINIB THERAPY AND PREDICTS MOLECULAR RESPONSE | Sieghart Sopper | ![]() |
![]() |
|||
596-P | BCR-ABL1 COMPOUND MUTANTS DISPLAY DIFFERENTIAL AND DOSE-DEPENDENT RESPONSES TO PONATINIB | Konstantin Byrgazov | ![]() |
![]() |
|||
597-P | IS THERE EFFECTIVE IMMUNE SURVEILLANCE AGAINST CHRONIC MYELOID LEUKAEMIA? NO. | Robert Gale | ![]() |
![]() |
|||
598-P | MUTATIONAL ANALYSIS IN BCR-ABL1 POSITIVE LEUKEMIA BY DEEP SEQUENCING BASED ON NANOPORE MINION TECHNOLOGY | Francesco Albano | ![]() |
![]() |
|||
599-P | THE AUTOMATED MOLECULAR TECHNIQUE "ULTRA" ALLOWS A SENSITIVE AND ACCURATE BCR-ABL1 QUANTIFICATION IN PATIENTS AFFECTED BY CHRONIC MYELOID LEUKEMIA. | Sara Galimberti | ![]() |
![]() |
|||
601-P | DURABLE TREATMENT-FREE REMISSION (TFR) FOLLOWING FRONTLINE NILOTINIB (NIL) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): ENESTFREEDOM 96-WK UPDATE | David Ross | ![]() |
![]() |
|||
602-P | RESPONSE DIFFERENCES IN THE BCR-ABL1 E13A2 AND E14A2 VARIANTS MAY BE A TECHNICAL QPCR ARTIFACT | Lasse Kjaer | ![]() |
![]() |
|||
603-P | 5-YR RESULTS FROM THE PIVOTAL PHASE 2 PONATINIB PACE TRIAL: EFFICACY, SAFETY AND LANDMARK ANALYSIS IN HEAVILY PRETREATED PATIENTS (PTS) WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) | Jorge Cortes | ![]() |
![]() |
|||
604-P | LONG-TERM FOLLOW-UP IN VERY ELDERLY PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH IMATINIB FRONTLINE | Isabella Capodanno | ![]() |
![]() |
|||
605-P | IMPACT OF ARTERIAL THROMBOTIC EVENTS ON THE LONG-TERM OUTCOME OF CHRONIC MYELOID LEUKEMIA (CML) PATIENTS TREATED IN FIRST-LINE WITH NILOTINIB: AN ANALYSIS OF THE GIMEMA CML WORKING PARTY | Gabriele Gugliotta | ![]() |
![]() |
|||
606-P | ASSESSMENT OF CHRONIC RENAL INJURY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE RECEIVING TYROSINE KINASE INHIBITORS | Qian Jiang | ![]() |
![]() |
|||
607-P | COMPARATIVE MONITORING OF MINIMAL RESIDUAL DISEASE (MRD) BY QPCR AND DIGITAL-PCR (DPCR) IN CHRONIC MYELOID LEUKEMIA PATIENTS ACHIEVING MAJOR OR DEEP MOLECULAR RESPONSE WITH TIROSIN-KINASE INHIBITORS | Simona Bernardi | ![]() |
![]() |
|||
608-P | OUTCOME OF BLAST PHASE CHRONIC MYELOID LEUKEMIA (CML-BP) IN THE TYROSINE KINASE INHIBITOR ERA | Chetasi Talati | ![]() |
![]() |
|||
609-P | EFFICACY OF SWITCHING TO DASATINIB IN CHRONIC MYELOID PATIENTS WITH LATE WARNING RESPONSES TO IMATINIB. STUDY OF THE ASSOCIATION OF RESPONSE TO DASATINIB TO IMMUNOLOGIC STATUS | Juan Luis Steegmann | ![]() |
![]() |
|||
610-P | GENETIC PREDICTION OF INSULIN RESISTANCE IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH NILOTINIB | Giovanni Caocci | ![]() |
![]() |
|||
611-P | THE EUROPE AGAINST CANCER PROTOCOL FOR BCR-ABL P210 TRANSCRIPT MEASUREMENT MAY OVERESTIMATE RESULTS FOR E13A2 VARIANT | Michal Gniot | ![]() |
![]() |
|||
612-P | ESTABLISHMENT OF IN VIVO AND IN VITRO MODEL OF X-LINKED SIDEROBLASTIC ANEMIA | Kei Saito | ![]() |
![]() |
|||
613-P | BENDAMUSTINE AND RITUXIMAB COMBINATION THERAPY FOR COLD AGGLUTININ DISEASE: RESULTS OF A PROSPECTIVE NORDIC TRIAL. | Sigbjørn Berentsen | ![]() |
![]() |
|||
615-P | IDENTIFICATION OF NEW PATHOGENIC MUTATIONS IN PATIENTS WITH RED BLOOD CELL MEMBRANE DISORDERS USING NEXT-GENERATION SEQUENCING | Maria Del Mar Mañu Pereira | ![]() |
![]() |
|||
616-P | CLINICAL FOLLOW-UP OF 378 PATIENTS WITH AUTOIMMUNE HEMOLYTIC ANEMIA: PROGNOSTIC IMPACT OF HEMOGLOBIN LEVELS, AUTOANTIBODY CLASS, AND RETICULOCYTOPENIA AT ONSET ON THE RELAPSE RISK AND OUTCOME | Bruno Fattizzo | ![]() |
![]() |
|||
618-P | USE OF PEGYLATED-CARBOXYHEMOGLOBIN BOVINE FOR THE TREATMENT OF SICKLE CELL DISEASE ASSOCIATED LEG ULCERS: RESULTS FROM A PHASE 2 SAFETY STUDY | Hemant Misra | ![]() |
![]() |
|||
619-P | NON-RENAL DETERMINANTS OF ENDOGENOUS ERYTHROPOIETIN LEVELS IN SICKLE CELL DISEASE | Kate Gardner | ![]() |
![]() |
|||
623-P | NHEJ-BASED GENE EDITING: A NOVEL GENE THERAPY APPROACH IN FANCONI ANEMIA HEMATOPOIETIC STEM AND PROGENITOR CELLS | Francisco Roman-Rodriguez | ![]() |
![]() |
|||
624-P | NOVEL, ENHANCED AND DUAL TARGETING CAR INVARIANT NKT CELL-BASED IMMUNOTHERAPY FOR CD1D+ B CELL MALIGNANCIES | Antonia Rotolo | ![]() |
![]() |
|||
625-P | A NOVEL CHIMERIC ANTIGEN RECEPTOR ENDOWS T CELLS WITH NK CELL-LIKE SPECIFICITY AND ATTACKS A WIDE RANGE OF HEMATOLOGICAL MALIGNANCIES AND CANCERS | Yasushi Kasahara | ![]() |
![]() |
|||
627-P | PRECLINICAL TESTING OF ADOPTIVE T-CELL RECEPTOR GENE TRANSFER IN COMBINATION WITH CHECKPOINT INHIBITORS AS A NOVEL THERAPY FOR MULTIPLE MYELOMA | Hakim Echchannaoui | ![]() |
![]() |
|||
630-P | SPECIFIC TARGETING OF ACUTE MYELOID LEUKEMIA BY THE USE OF ENGINEERED CIK (CYTOKINE-INDUCED KILLER) CELLS EXPRESSING THE ANTI-CD33 CHIMERIC ANTIGEN RECEPTOR (CAR). | Maria Rotiroti | ![]() |
![]() |
|||
632-P | A SINGLE INSTITUTIONAL EXPERIENCE OF 261 PATIENTS WITH LARGE GRANULAR LYMPHOCYTIC LEUKEMIA | Magali Van den Bergh | ![]() |
![]() |
|||
633-P | ONGOING PHASE 1/2 STUDY OF INCB050465, A SELECTIVE PI3K-DELTA INHIBITOR, FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY B-CELL MALIGNANCIES (CITADEL-101) | Andres Forero-Torres | ![]() |
![]() |
|||
634-P | PHASE IIIB RANDOMIZED STUDY OF LENALIDOMIDE PLUS RITUXIMAB (R2) FOLLOWED BY LENALIDOMIDE VS. RITUXIMAB MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY NHL: ANALYSIS OF FOLLICULAR LYMPHOMA PATIENTS | John Burke | ![]() |
![]() |
|||
635-P | A DOUBLE-BLIND, RANDOMIZED PHASE 3 STUDY TO COMPARE EFFICACY AND SAFETY OF CT-P10 TO INNOVATOR RITUXIMAB IN COMBINATION WITH CVP IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED FOLLICULAR LYMPHOMA | Michinori Ogura | ![]() |
![]() |
|||
636-P | DURABLE DISEASE CONTROL OF EARLY MYCOSIS FUNGOIDES PATIENTS TREATED WITH LOW-DOSE INTERFERON-ALPHA2B AND PUVA | Serena Rupoli | ![]() |
![]() |
|||
639-P | CLONAL B-CELL LYMPHOCYTOSIS OF MARGINAL ZONE ORIGIN (CBL-MZ): A PROSPECTIVE REGISTRATIONAL STUDY ON 96 CASES | Christina Kalpadakis | ![]() |
![]() |
|||
640-P | SAFETY OF SUBCUTANEOUS ADMINISTRATION OF RITUXIMAB DURING THE FIRST-LINE TREATMENT OF PATIENTS WITH NON-HODGKIN LYMPHOMA: THE MABRELLA STUDY | Carlos Panizo | ![]() |
![]() |
|||
642-P | MICAFUNGIN VERSUS LIPOSOMAL AMPHOTERICIN B FOR EMPIRICAL ANTIFUNGAL THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: A RANDOMIZED CONTROLLED TRIAL | Tatsuo Oyake | ![]() |
![]() |
|||
643-P | ANTIFUNGAL DRUGS INFLUENCE NEUTROPHIL EFFECTOR FUNCTIONS IN VITRO AND MODULATE PULMONARY DAMAGE IN INVASIVE ASPERGILLOSIS | Daniel Teschner | ![]() |
![]() |
|||
644-P | CHARACTERISTICS AND OUTCOME OF PULMONARY INFILTRATES IN ACUTE LEUKEMIA CLASSIFIED ACCORDING TO EORTC/MSG CRITERIA OF INVASIVE FUNGAL INFECTION: A PROSPECTIVE STUDY BY THE RETE EMATOLOGICA LOMBARDA | Chiara Cattaneo | ![]() |
![]() |
|||
645-P | ANTIFUNGAL PROPHYLAXIS WITH CD101 IN IMMUNOSUPPRESSED MOUSE MODELS OF CANDIDIASIS, ASPERGILLOSIS, AND PNEUMOCYSTIS PNEUMONIA (PCP) | Voon Ong | ![]() |
![]() |
|||
646-P | SURGICAL MANAGEMENT OF INVASIVE FUNGAL INFECTIONS IN ADULT LEUKAEMIA PATIENTS – EXPERIENCE FROM A LARGE TERTIARY CENTRE IN SOUTH-EAST ASIA | Chandramouli Nagarajan | ![]() |
![]() |
|||
647-P | INFECTIONS IN MULTIPLE MYELOMA ARE FREQUENT AND PREDOMINANTLY CAUSED BY BACTERIA: RESULTS OF A 12-YEAR SURVEY FROM A SINGLE CENTER | Marie Von Lilienfeld-Toal | ![]() |
![]() |
|||
648-P | HUMAN L-FICOLIN POLYMORPHISMS CONTRIBUTE TO SUSCEPTIBILITY TO INFECTIONS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA | Ulf Schnetzke | ![]() |
![]() |
|||
649-P | PREDICTIVE FACTORS OF RESPONSE TO EPOETIN THETA IN CHEMOTHERAPY-INDUCED ANEMIA: A FRENCH MULTICENTER OBSERVATIONAL STUDY (PIVOINE). | Philippe RODON | ![]() |
![]() |
|||
650-P | TIMING OF DEFIBROTIDE INITIATION POST-DIAGNOSIS OF HEPATIC VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME AFTER PRIMARY CHEMOTHERAPY: EXPLORATORY ANALYSIS OF AN EXPANDED-ACCESS PROTOCOL | Paul Richardson | ![]() |
![]() |
|||
651-P | ADAMTS-13 REGULATES NEUTROPHIL RECRUITMENT IN A MOUSE MODEL OF INVASIVE PULMONARY ASPERGILLOSIS | Astrid Hasibeder | ![]() |
![]() |
|||
652-P | IDENTIFICATION OF THE SPECIFIC HEMATOPOIETIC STEM CELL POPULATIONS RESPONSIBLE FOR FAILURE TO HYPOMETHYLATING AGENTS IN MYELODYSPLASTIC SYNDROMES | Irene Gañán-Gómez | ![]() |
![]() |
|||
655-P | CLONAL EVOLUTION OF STAG2 AND NRAS DURING PROGRESSION FROM MDS TO SAML ASSESSED BY WHOLE-EXOME AND TARGETED-DEEP SEQUENCING | Marta Martín-Izquierdo | ![]() |
![]() |
|||
656-P | PROGRESSION OF MDS TO AML FEATURES GAIN OF SINGLE DRIVER MUTATIONS WITH CONSEQUENT CHANGES IN CLONAL COMPOSITION AND OCCURRENCE OF MULTIPLE CLONES WITH MUTATIONS IN IDENTICAL GENES | Juliane Stosch | ![]() |
![]() |
|||
657-P | PRECLINICAL MODELING OF MYELODYSPLASTIC SYNDROMES | Kevin Rouault-Pierre | ![]() |
![]() |
|||
658-P | MYELODYSPLASTIC SYNDROMES WITH IRON OVERLOAD ARE CHARACTERIZED BY A SWITCH FROM OXIDATIVE PHOSPHORYLATION TO GLYCOLYSIS AND THIS DEFECT IS PARTIALLY RESTORED BY IRON CHELATION. A FISM STUDY | Daniela Cilloni | ![]() |
![]() |
|||
659-P | V-SET AND IMMUNOGLOBULIN DOMAIN-CONTAINING 4 (VSIG4) EXPRESSED ON MONOCYTES INCLUDING TUMOR-ASSOCIATED MACROPHAGES SUPPRESSED ANTITUMOR IMMUNE RESPONSES IN MYELODYSPLASTIC SYNDROMES | Yasuko Kuribayashi-Hamada | ![]() |
![]() |
|||
660-P | TRANSCRIPTOME ASSESSMENT OF DNA REPAIR GENES IN CHRONIC MYELOMONOCYTIC LEUKEMIA: SYNTHETIC LETHALITY TARGETS | Ana María Hurtado López | ![]() |
![]() |
|||
661-P | DIFFERENTIAL DIAGNOSIS BETWEEN MYELODYSPLASTIC SYNDROMES AND NON-CLONAL CYTOPENIAS BY FLOW CYTOMETRY ANALYSIS USING A MYELOID MATURATION DATABASE | MTeresa Cedena | ![]() |
![]() |
|||
663-P | EPIGENETIC DRUG TREATMENT GLOBALLY INDUCES CRYPTIC TRANSCRIPTION START SITES ENCODED IN LONG TERMINAL REPEATS (LTRS) | Michael Daskalakis | ![]() |
![]() |
|||
665-P | IMPACT OF MARROW COMPLETE RESPONSE IN THE NATURAL HISTORY OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) AND CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) TREATED WITH HYPOMETHYLATING AGENTS | Ana Alfonso Pierola | ![]() |
![]() |
|||
667-P | RATE AND CAUSES OF 5-AZACYTIDINE DISCONTINUATION AND SUBSEQUENT THERAPEUTIC OPTIONS IN 418 MDS PATIENTS FROM THE ITALIAN MDS REGISTRY OF FONDAZIONE ITALIANA SINDROMI MIELODISPLASTICHE (FISM) | Marino Clavio | ![]() |
![]() |
|||
668-P | COMBINATION OF DEEP PHENOTYPING AND TARGETED NEXT GENERATION SEQUENCING AS A DIAGNOSTIC TOOL IN CHILDREN WITH SUSPECTED MDS | Eleni Louka | ![]() |
![]() |
|||
669-P | OUTCOMES IN PATIENTS ALLOCATED TO NO-ASCT BASED ON DEPTH OF RESPONSE: INITIAL RESULTS OF A PHASE 2 TRIAL ASSESSING THE IMPACT OF MINIMAL RESIDUAL DISEASE (MRD) IN PATIENTS WITH DEFERRED ASCT (PADIMAC) | Kwee Yong | ![]() |
![]() |
|||
670-P | PROPORTION AND COMPOSITION OF BONE MARROW LYMPHOCYTE POOL AT BASELINE CORRELATES WITH OUTCOME IN MM PATIENTS AFTER RVD AND ASCT | Sini Luoma | ![]() |
![]() |
|||
671-P | VALUE OF THE 18F-FDG PET-CT IN THE IDENTIFYING BONE INVOLVEMENT EITHER AT DIAGNOSIS OR DURING FOLLOW-UP OF PATIENTS AFFECTED BY MULTIPLE MYELOMA. | Sara Galimberti | ![]() |
![]() |
|||
673-P | PROGNOSTIC SIGNIFICANCE OF CLONAL CIRCULATING PLASMA CELLS BY MULTI-PARAMETRIC FLOW CYTOMETRY IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION | Surbhi Sidana | ![]() |
![]() |
|||
674-P | RENAL IMPAIRMENT IN MYELOMA - PATIENT CHARACTERISTICS, TREATMENT MODALITIES, STEM CELL TRANSPLANT & OUTCOMES FROM THE AUSTRALIAN AND NEW ZEALAND MYELOMA REGISTRY | Joy Ho | ![]() |
![]() |
|||
676-P | AN OPEN-LABEL, PHASE 1B STUDY (MMY1001) OF DARATUMUMAB COMBINED WITH CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (KRD) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) | Saad Usmani | ![]() |
![]() |
|||
677-P | GENE EXPRESSION CLASSIFIER EMC92/SKY92 AND REVISED ISS ROBUSTLY IDENTIFY HIGH-RISK MULTIPLE MYELOMA IN ELDERLY PATIENTS OF THE HOVON-87/NMSG-18 STUDY | Rowan Kuiper | ![]() |
![]() |
|||
678-P | MULTIPLE MYELOMA AND COMORBIDITY: A POPULATION-BASED STUDY | Ingigerdur Solveig Sverrisdottir | ![]() |
![]() |
|||
679-P | DETECTION OF NEW EMERGING CLONES DURING TREATMENT BY NGS ALLOWS A BETTER RISK PREDICTION ON MULTIPLE MYELOMA PATIENTS | Beatriz Sanchez-Vega | ![]() |
![]() |
|||
680-P | FINAL RESULTS OF PHASE (PH) 1/2 STUDY OF CARFILZOMIB, POMALIDOMIDE, AND DEXAMETHASONE (KPD) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): A MULTI-CENTER MMRC STUDY | Andrzej Jakubowiak | ![]() |
![]() |
|||
681-P | PANOBINOSTAT INDUCES CD38 UPREGULATION AND AUGMENTSTHE ANTI-MYELOMA EFFICACY OF DARATUMUMAB | Estefania Garcia-Guerrero | ![]() |
![]() |
|||
683-P | THE IMPACT OF THE INTRODUCTION OF BORTEZOMIB ON DIALYSIS INDEPENDENCE IN MULTIPLE MYELOMA PATIENTS WITH RENAL FAILURE: A NATIONWIDE DUTCH POPULATION-BASED STUDY | Berdien Oortgiesen | ![]() |
![]() |
|||
684-P | TREATMENT WITH POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA AND LIGHT CHAIN (AL) AMYLOIDOSIS | Paolo Milani | ![]() |
![]() |
|||
685-P | MYOCARDIAL UPTAKE OF 99MTC-DPD IN PATIENTS WITH AL AMYLOIDOSIS | Carlos De Miguel | ![]() |
![]() |
|||
686-P | WHEN PERFORMANCE OF CYTOGENETICS MATTERS: A POPULATION-BASED STUDY IN THE NETHERLANDS ON NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS | Mirian Brink | ![]() |
![]() |
|||
687-P | AN UPDATED ADJUSTED COMPARISON SUGGESTS DARATUMUMAB IS ASSOCIATED WITH PROLONGED SURVIVAL COMPARED WITH STANDARD OF CARE THERAPIES IN HEAVILY PRE-TREATED AND HIGH REFRACTORY MULTIPLE MYELOMA PATIENTS | Shaji Kumar | ![]() |
![]() |
|||
688-P | PREDICTORS OF EARLY DEATH RELATED TO ACTIVE MULTIPLE MYELOMA IN ELDERLY PATIENTS RECEIVING OPTIMIZED FRONTLINE TREATMENT COMBINATIONS | Paula Rodriguez Otero | ![]() |
![]() |
|||
689-P | MPL ACTIVATION DIRECTLY INDUCES FIBROCYTE DIFFERENTIATION TO CAUSE MYELOFIBROSIS | Takaaki Maekawa | ![]() |
![]() |
|||
690-P | ENGRAFTMENT OF PRIMARY MYELOFIBROSIS BONE MARROW-DERIVED CD14+ MONOCYTES IN NOD-SCID-? MICE | Taghi Manshouri | ![]() |
![]() |
|||
691-P | ESTABLISHMENT OF AN IN VITRO MODEL FOR THE SKEWED MEGAKARYOPOIESIS BY CALRETICULIN MUTATION IN HUMAN CELLS | Hiraku Takei | ![]() |
![]() |
|||
692-P | QUANTITATIVE PROTEOME HETEROGENEITY IN MYELOPROLIFERATIVE NEOPLASM SUBTYPES AND ASSOCIATION WITH JAK2 MUTATION STATUS | Nuria Yuste | ![]() |
![]() |
|||
693-P | THE NOVEL SWITCH CONTROL INHIBITOR DCC-2618 COUNTERACTS GROWTH AND SURVIVAL OF VARIOUS NEOPLASTIC CELLS, INCLUDING MAST CELLS, EOSINOPHILS, AND MONOCYTES, IN PATIENTS WITH SYSTEMIC MASTOCYTOSIS | Mathias Schneeweiss | ![]() |
![]() |
|||
694-P | DISTRIBUTION OF MUTATIONS IN DRIVER AND NON-DRIVER GENES ACCORDING TO CLONAL HEMATOPOIESIS IN ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA | Alicia Senín | ![]() |
![]() |
|||
695-P | RUXOLITINIB/NILOTINIB/PREDNISOLONE COMBINATION: A PROMISING NOVEL TREATMENT FOR MYELOFIBROSIS | Joaquín Martínez-López | ![]() |
![]() |
|||
696-P | INTERLABORATORY ASSESSMENT OF MUTATION DETECTION IN MYELOID MALIGNANCIES BY TARGETED NEXT-GENERATION SEQUENCING | Concepción Fernández-Rodríguez | ![]() |
![]() |
|||
697-P | METHYLATION AGE IN MPN PATIENTS AS A CORRELATE FOR DISEASE STATUS, ALLELE BURDEN AND THERAPEUTIC RESPONSE | Suzanne McPherson | ![]() |
![]() |
|||
702-P | SAFETY AND EFFICACY OF RUXOLITINIB (RUX) IN ELDERLY PATIENTS (= 75 YEARS) WITH MYELOFIBROSIS (MF): AN ANALYSIS FROM THE PHASE 3B, EXPANDED-ACCESS JUMP STUDY | Pia Raanani | ![]() |
![]() |
|||
703-P | PROGNOSTIC RISK MODELS FOR TRANSPLANT DECISION-MAKING IN MYELOFIBROSIS | Juan Carlos Hernández-Boluda | ![]() |
![]() |
|||
704-P | LEUKEMIC TRANSFORMATION AND SECOND CANCERS IN 3649 HIGH RISK ET PATIENTS IN THE EXELS STUDY | Gunnar Birgegård | ![]() |
![]() |
|||
705-P | EPIDEMIOLOGY, OUTCOME AND RISK FACTORS FOR INFECTIOUS COMPLICATIONS IN MF PATIENTS RECEIVING RUXOLITINIB. A MULTICENTER STUDY ON 373 PATIENTS | Nicola Polverelli | ![]() |
![]() |
|||
706-P | TREATMENT AND MANAGEMENT OF PATIENTS WITH MPNS—FINDINGS FROM THE INTERNATIONAL MPN LANDMARK SURVEY | Steffen Koschmieder | ![]() |
![]() |
|||
709-P | MASITINIB FOR TREATMENT OF SEVERELY SYMPTOMATIC INDOLENT SYSTEMIC MASTOCYTOSIS: ADDITIONAL EFFICACY ANALYSES FROM THE RANDOMIZED, PLACEBO-CONTROLLED, PHASE 3 STUDY | Olivier Hermine | ![]() |
![]() |
|||
710-P | THERAPY RESPONSE AND LONG-TERM OUTCOME OF 71 ADULT PATIENTS WITH HEMATOLOGICAL MALIGNANCY-ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: A SINGLE INSTITUTION EXPERIENCE | Maciej Machaczka | ![]() |
![]() |
|||
712-P | SEQUENCING OF THE HYPOXIA PATHWAY GENES IN PATIENTS WITH CONGENITAL ERYTHROCYTOSES BY NEXT GENERATION SEQUENCING | Francois Girodon | ![]() |
![]() |
|||
713-P | CHARACTERIZATION OF CD34+ HEMATOPOIETIC PRECURSORS IN INDOLENT SYSTEMIC MASTOCYTOSIS AND THEIR POTENTIAL ROLE IN EARLY DISSEMINATION OF THE DISEASE. | Andrea Mayado | ![]() |
![]() |
|||
714-P | MONOALLELIC VARIANTS IN GENES RELATED TO FAMILIAL HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: REPORT FROM THE ITALIAN REGISTRY | Laura Vinas | ![]() |
![]() |
|||
716-P | NEUROLOGICAL INVOLVEMENT IN EVANS SYNDROME AND CHRONIC HEMOLYTIC AUTOIMMUNE ANEMIA OF CHILDREN: DESCRIPTION, EVOLUTION AND GENETICS | Thomas Pincez | ![]() |
![]() |
|||
717-P | AUTOIMMUNE NEUTROPENIA OF CHILDHOOD SECONDARY TO OTHER AUTOIMMUNE DISORDERS: DATA FROM THE ITALIAN NEUTROPENIA REGISTRY | Piero Farruggia | ![]() |
![]() |
|||
718-P | PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT DURING PREGNANCY | Maria Vinogradova | ![]() |
![]() |
|||
719-P | LONG-TERM RESPONSE TO ORAL ELIGLUSTAT IN TREATMENT-NAÏVE ADULTS WITH GAUCHER DISEASE TYPE 1: FINAL EFFICACY AND SAFETY RESULTS FROM A PHASE 2 CLINICAL TRIAL AFTER 8 YEARS OF TREATMENT | Elena Lukina | ![]() |
![]() |
|||
721-P | BIOLOGICAL CHARACTERIZATION OF ITP PATIENTS THAT ARE NON-RESPONDERS TO TRADITIONAL THERAPIES | Nuria Revilla | ![]() |
![]() |
|||
725-P | ATORVASTATIN IMPROVE THE PROGNOSIS OF ADULT PATIENTS WITH CORTICOSTEROID-RESISTANT IMMUNE THROMBOCYTOPENIA VIA ENHANCING BONE MARROW ENDOTHELIAL CELL FUNCTION | Xie-Na Cao | ![]() |
![]() |
|||
726-P | PLATELET DESIALYLATION IS A NOVEL MECHANISM AND A THERAPEUTIC TARGET IN THROMBOCYTOPENIA DURING SEPSIS: AN OPEN-LABEL, MULTICENTER, RANDOMIZED CONTROLLED TRIAL | Xin Li | ![]() |
![]() |
|||
727-P | SAFETY AND EFFICACY OF LONG-TERM OPEN-LABEL DOSING OF SUBCUTANEOUS (SC) ROMIPLOSTIM IN CHILDREN WITH IMMUNE THROMBOCYTOPENIA (ITP) | James Bussel | ![]() |
![]() |
|||
728-P | IMPACT OF VENETOCLAX ON THE QUALITY OF LIFE OF CLL PATIENTS RELAPSED/REFRACTORY TO B-CELL RECEPTOR (BCR) SIGNALING PATHWAY INHIBITOR TREATMENT | William Wierda | ![]() |
![]() |
|||
729-P | THE ROLE OF PSYCHOLOGICAL VARIABLES FOR TYROSINE KINASE INHIBITORS (TKI) DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS: IMPLICATION FOR MEDICAL DECISION MAKING PRACTICE | Silvia Riva | ![]() |
![]() |
|||
730-P | BUDGET IMPACT ANALYSIS OF BIOSIMILAR RITUXIMAB (CT-P10) FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKAEMIA IN THE 28 EU MEMBER STATES | Fanni Rencz | ![]() |
![]() |
|||
731-P | AN INVESTIGATION INTO THE NEEDS AND PRIORITIES OF PATIENTS WITH MULTIPLE MYELOMA DURING REMISSION – IMPLICATIONS FOR RE-DESIGNING PATIENT-CENTRED HEALTHCARE SYSTEMS. | Dunnya De-Silva | ![]() |
![]() |
|||
732-P | COST-EFFECTIVENESS OF RITUXIMAB IN ADDITION TO STANDARD OF CARE CHEMOTHERAPY FOR ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA | Matthew Seftel | ![]() |
![]() |
|||
734-P | RADIATION EXPOSURE FROM CT IMAGING AND CHILDHOOD LEUKEMIA: A NATIONWIDE CASE-CONTROL STUDY | Atte Nikkilä | ![]() |
![]() |
|||
735-P | HEALTHCARE RESOURCE UTILIZATION WITH IXAZOMIB OR PLACEBO PLUS LENALIDOMIDE-DEXAMETHASONE IN THE RANDOMIZED, DOUBLE-BLIND, PHASE 3 TOURMALINE-MM1 STUDY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) | Parameswaran Hari | ![]() |
![]() |
|||
736-P | MANAGEMENT, ECONOMIC AND SOCIAL IMPACT OF SUB-CUTANEOUS RITUXIMAB ADMINISTRATION IN LYMPHOPROLIFERATIVE MALIGNANCIES | Ombretta Annibali | ![]() |
![]() |
|||
737-P | EFFECT OF IMPROVEMENTS OF SURVIVAL, POPULATION AGING AND IMWG´14 CRITERIA ON INCIDENCE AND PREVALENCE OF MULTIPLE MYELOMA | Violeta Martínez-Robles | ![]() |
![]() |
|||
738-P | HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ISOLATED EXTRAMEDULLARY RELAPSE OF ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN | Maria Gabelli | ![]() |
![]() |
|||
739-P | PREDICTIVE FACTORS FOR DEVELOPING VENO-OCCLUSIVE DISEASE IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH INOTUZUMAB OZOGAMICIN FOLLOWED BY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION | Partow Kebriaei | ![]() |
![]() |
|||
740-P | DEFIBROTIDE EFFICACY AND SAFETY IN PATIENTS WITH HEPATIC VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) DIAGNOSED AFTER DAY 21: ANALYSIS OF FINAL DATA FROM AN EXPANDED-ACCESS PROGRAM | Paul Richardson | ![]() |
![]() |
|||
741-P | ALLO-HCT FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA – 12 YEARS OF EXPERIENCE | Miroslaw Markiewicz | ![]() |
![]() |
|||
743-P | HAPLOIDENTICAL ALLOGENEIC STEM CELL TRANSPLANT IN SEVERE THALASSEMIA PATIENTS | Suradej Hongeng | ![]() |
![]() |
|||
744-P | AUGMENTATION OF FLUDARABINE AND BUSULFAN-BASED MYELOABLATIVE REGIMEN WITH THIOTEPA IMPROVES OUTCOMES WITH NO ADDED TOXICITY IN ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA | Vipul sharad Sheth | ![]() |
![]() |
|||
745-P | PROGNOSTIC TOOLS CAN PROVIDE PERSONALIZED OUTCOMES PREDICTION AFTER ALLOGENEIC HCT IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES | Christina Cho | ![]() |
![]() |
|||
747-P | FACTORS PREDICTING GRAFT VERSUS HOST DISEASE-FREE, RELAPSE-FREE SURVIVAL AFTER ALLOGENEIC TRANSPLANTATION. COMPARISON ATTENDING TO TWO DIFFERENT DEFINITIONS AND BENEFICT OF HAPLOIDENTICAL DONOR. | Estefanía Pérez López | ![]() |
![]() |
|||
748-P | EFFICACY AND SAFETY OF DEFIBROTIDE IN THE TREATMENT OF HEPATIC VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION: FINAL SUBGROUP RESULTS | Paul Richardson | ![]() |
![]() |
|||
749-P | GENERATION OF IMMORTAL MURINE HEMATOPOIETIC STEM/PROGENITOR CELL LINES FROM TRANSGENIC MICE | Eszter Doma | ![]() |
![]() |
|||
751-P | MESENCHYMAL STROMAL CELL IRRADIATION INTERFERES WITH THE ADIPOGENIC/OSTEOGENIC DIFFERENTIATION BALANCE IMPROVING THEIR HEMATOPOIETIC-SUPPORTING ABILITY | Silvia Preciado Pérez | ![]() |
![]() |
|||
752-P | DYSFUNCTION OF BONE MARROW MESENCHYMAL STEM CELLS FROM PATIENTS WITH PROLONGED ISOLATED THROMBOCYTOPENIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION CAN BE IMPROVED BY N-ACETYL-L-CYSTEINE | Yang Song | ![]() |
![]() |
|||
753-P | INHIBITORS OF APOPTOSIS PROTEINS (IAPS) MODULATE GASTROINTESTINAL GVHD IN MURINE EXPERIMENTAL BMT MODELS | Tomomi Toubai | ![]() |
![]() |
|||
754-P | GRAFT-VERSUS HOST DISEASE (GVHD) DEVELOPMENT AFTER BONE MARROW TRANSPLANTATION IS NOT INFLUENCED BY TH9 CELLS | Gudrun Strauss | ![]() |
![]() |
|||
755-P | IMPROVED HSC ENGRAFTMENT IN A MOUSE MODEL OF HEMATOPOIETIC STEM CELL GENE THERAPY MEDIATED BY MSCS | Maria Fernandez-Garcia | ![]() |
![]() |
|||
756-P | EFFECT OF POMALIDOMIDE ON T CELL POLARIZATION IS MEDIATED THROUGH EPIGENETIC MODIFCATIONS. | Isabel Alvarez Laderas | ![]() |
![]() |
|||
757-P | MESENCHYMAL STEM CELLS (MSCS) ATTENUATE CUTANEOUS SCLERODERMATOUS GRAFT-VERSUS-HOST DISEASE (SCL-GVHD) THROUGH INHIBITION OF IMMUNE CELL INFILTRATION IN A MOUSE MODEL | Ji-Young Lim | ![]() |
![]() |
|||
758-P | C57BL/6 SUBTRAINS SHOW DIFFERENCES IN HEMATOPOIETIC REPOPULATION | Antonio Morales Hernandez | ![]() |
![]() |
|||
759-P | GWAS RESULTS IN RED BLOOD CELL PHENOTYPES AND THEIR RELATIONSHIP WITH THROMBOSIS | Remacha Angel F. | ![]() |
![]() |
|||
760-P | ESSENTIAL THROMBOCYTHEMIA (ET) AND POLYCYTHEMIA VERA (PV) PATIENTS SHOW AN INCREASED THROMBUS FORMATION IN A DYNAMIC MODEL OF PLATELET ADHESION | Alfonso Vignoli | ![]() |
![]() |
|||
761-P | DOAC ASSOCIATED MAJOR GASTROINTESTINAL BLEEDING: REAL LIFE EXPERIENCE FROM A UNIVERSITY TEACHING HOSPITAL, UK | Buddhika Badugama | ![]() |
![]() |
|||
763-P | INCIDENCE OF VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING LOWER LIMB SURGICAL REVASCULARIZATION: IS THROMBOPROPHYLAXIS WARRANTED? | Pinar Smith | ![]() |
![]() |
|||
764-P | THE ROLE OF INFLAMMATION IN THROMBOEMBOLISM IN RESECTABLE RENAL CELL CARCINOMA PATIENTS | Hyunkyung Park | ![]() |
![]() |
|||
765-P | GENETIC AND ENVIRONMENTAL RELATIONSHIP BETWEEN VITAMIN B12, FOLATE AND HOMOCYSTEINE AND SUSCEPTIBILITY TO THROMBOSIS IN THE GAIT 2 PROJECT. RESULTS OF A GWAS ANALYSIS. | Remacha Angel F. | ![]() |
![]() |
|||
766-P | CELLULAR ORIGIN OF CIRCULATING MICROPARTICLES (MP) ACCORDING TO SOMATIC MUTATIONS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS (MPN) | Carmen Tartari | ![]() |
![]() |
|||
767-P | ARE WE TESTING APPROPRIATELY FOR THE LUPUS ANTICOAGULANT? | Joe Sharif | ![]() |
![]() |
|||
768-P | RESULTS OF USING BRIDGING THERAPY WITH SODIUM BEMIPARIN AT THERAPEUTIC-DOSE | María Almudena García Ruiz | ![]() |
![]() |
22-25 June 2017 Madrid
![]() |
![]() |
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. ![]() To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. ![]() |
![]() |
||
![]() |
|